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ABBREVIATIONS 
 
153N-6 = MC1R antagonist 
ACTA2 = α-Smooth-Muscle Actin gene 
ACTH = Adrenocorticotropic hormone 
AgRP = Agouti-related protein 
ASIP = Agouti signaling protein 
AUC = area under curve 
Ca2+ = Calcium 
cAMP = Cyclic adenosine mono phosphate 
CNN1 = Calponin gene 
CNS = Central nervous system 
CREB = cAMP response element-binding  
CVD = Cardiovascular disease 
DES = Drug-eluting stent 
dPCR = digital PCR 
EC = Endothelial cell 
ECM= Extracellular matrix 
EL = Extracellular loop 
GPCR = G protein-coupled receptor 
GRK = G protein-coupled receptor kinase 
HAoEC = Human aortic endothelial cell 
HAoSMC = Human aortic smooth muscle cell 
HCAEC = Human coronary artery endothelial cell 
HDMEC = human dermal microvascular endothelial cell  
HMEC-1 = transformed human dermal endothelial cell 
HSE = heat shock response element 
HSF1 = Heat shock factor 1 
HSP27 = Heat shock protein 27 
ICC = Immunocytochemistry 
IHC = Immunohistochemistry 
IP3 = Inositol triphosphate 
JKC 363 = MC4R specific antagonist 
MC(1-5)R = Melanocortin (1-5) receptor 
MCS = Melanocortin system 
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MK2 = MAPK activated protein kinase 2 
MSG-606 = MC1R specific antagonist  
MSH-OE = transgenic mice overexpressing MSH  
NF-kB = Nuclear factor-kB 
NKX2.5 = NK2 Homeobox-5 
NO = Nitric oxide 
ORF = open reading frame 
p38MAPK = p38 mitogen-activated protein kinase 
PC = Pro-hormone convertases 
PDGF = platelet-derived growth factor 
PKA-C = protein kinase A-C 
POMC = Proopiomelanocortin 
qRT-PCR = Quantitative real time PCR 
SERCA = sarco/endoplasmic reticulum Ca2+ATPases 
SM22α = Smooth-Muscle-22-α  
SMC = Smooth muscle cell 
SM-MHC = Smooth muscle myosin heavy chain 
SOX9 = SRY-Box 9 
TGLN = SM22α gene 
TM = Transmembrane 
VEGF = Vascular endothelial growth factor 
WB = Western blot 
α-(β-γ)-MSH = α-(β-γ)-melanocyte stimulating hormone (MCR agonist) 
α-SMA = α-Smooth-Muscle Actin  
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Background: Vascular remodeling is a pathological process central to many cardiovascular 
diseases (CVDs). Vascular injury promotes a complex interplay between distinct cell 
populations in the vessel wall that results in endothelial dysfunction and local inflammation, 
which in turn stimulate vascular smooth muscle cell (SMC) proliferation and extracellular 
matrix (ECM) deposition, leading to neointimal thickening and stenosis. Different signaling 
pathways, including the melanocortin system (MCS), modulate vascular inflammation and 
oxidative stress. The MCS refers to a set of hormonal and paracrine signaling pathways that 
include five G protein-coupled receptors (GPCRs), peptide agonists derived from the post-
translational processing of the proopiomelanocortin (POMC) prohormone, ancillary proteins, 
and endogenous antagonists. This system regulates a remarkably diverse array of 
physiological functions and host reactions. Preclinical investigations indicate that activation of 
certain melanocortin receptor (MCR) subtypes, primarily MC1R, could be a novel strategy to 
control inflammatory disorders. A local MCS has been described in endothelial cells (EC) of the 
cutaneous and cerebral microcirculation. The melanocortin alpha-melanocyte stimulating 
hormone (α-MSH) has been shown to modulate blood vessel tone by enhancing nitric oxide 
(NO)-cyclic-guanosine mono-phosphate dependent relaxation responses through endothelial 
MC1R. Besides, treatment with MCR agonists was able to prevent the development of vascular 
dysfunction and attenuate plaque inflammation in pre-established atherosclerosis. We sought 
to investigate whether human macrovascular ECs and SMCs express locally any MCR and what 
function MCRs exert.  
Methods: Expression of MCS components in primary human aortic (HAoEC), coronary artery 
ECs (HCAEC) and human aortic smooth muscle cells (HAoSMC) were assessed by real-time PCR 
(qRT-PCR), western blot (WB), immunocytochemistry (ICC) and immunohistochemistry (IHC). 
Intracellular cyclic adenosine-mono-phosphate (cAMP) concentrations were measured by an 
ELISA assay. Intracellular EC calcium (Ca2+) concentrations were analyzed using a fluorescent 
Ca2+ indicator. Gap closure assays were used for assessing in vitro cell migration of ECs and 
SMCs. SMC transmigration was assessed by a transwell migration assays along a 
chemoattractant gradient (chemotaxis), and proliferation by incorporation and measurement 
of a nucleoside analog in newly synthesized DNA. Genome-wide gene expression profiling was 
performed in migrating HAoECs and HAoSMCs after stimulation with α-MSH in time-course 
experiments, using microarrays and RNA sequencing, respectively. SMC phenotypic changes 
and associated biomarkers were visualized and measured by ICC and qPCR. 
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Results: We showed that primary human aortic ECs and SMCs express functionally active 
MCRs. ECs express MC1R, but not other MCR subtypes nor the precursor hormone POMC. 
MC1R engagement with α-MSH, its highest-affinity natural ligand, accelerates cell migration 
in an in vitro directional migration assay. This was associated with enhancing in Ca2+ signaling 
and inhibition of cAMP elevation. Time-course genome-wide expression analysis in ECs 
undergoing directional migration assay allowed identifying dynamic co-regulation of genes 
involved in the extracellular matrix-receptor interaction, vesicle-mediated trafficking, and 
metal sensing: all these pathways have a well-established influence on EC motility. 
SMCs express MC1R and MC4R, but not POMC. In vitro stimulation with α-MSH promoted 
human aortic SMC differentiation from a synthetic to a contractile phenotype with a spindle-
shape conformation. α-MSH promoted significant human aortic SMC elongation with peak 
effects at 6-12 h after treatment. Stimulation with α-MSH enhanced gene and protein 
expression of α-Smooth-Muscle Actin (α-SMA) and Smooth-Muscle-22-α (SM22α), which are 
markers of the contractile phenotype. MCR activation by α-MSH slowed down migration both 
in the gap-closure assay (peak effect at 9-12 h) and in the transwell migration assay. We 
confirmed that MC1R is involved in this process because its inhibition with a specific 
antagonist (MSG-606) restored the normal migration rate. Furthermore, MCR activation 
slightly decreased HAoSMC proliferation. We then investigated which pathways were 
activated downstream the receptor in migrating SMC, by analyzing the transcriptome and 
specific phosphoproteins. We found a negative modulation of the p38 mitogen-activated 
protein kinase (p38MAPK)/heat shock factor 1 (HSF1) pathway along with a significant 
reduction in p38-MAPK phosphorylation, which likely is the mechanism of action underlying 
MC1R-related modulation of SMC migration. 
Conclusions: These results provide evidence of a novel function of peripherally expressed 
MCRs, i.e. regulation of EC and SMC motility, ultimately contributing to vessel homeostasis. In 
addition, this is the first study that seeks to uncover the possible influences of MCRs expressed 
in macrovascular arteries on the pathophysiology of vascular remodeling. Indeed, results from 
this study suggest novel, potentially promising therapeutic targets for prevention and healing 
of vascular remodeling: targeting the MCRs may result in controlling vessel inflammation, 
healing endothelial dysfunction, and inhibiting SMC phenotypic switching. 
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Introduzione: il rimodellamento vascolare è un evento comune in molte patologie 
cardiovascolari. Il danno vascolare attiva complesse interazioni tra le cellule all’interno della 
parete del vaso che portano a disfunzione endoteliale, infiammazione locale, proliferazione e 
migrazione delle cellule muscolari lisce (SMC) e deposizione di nuova matrice extracellulare 
(ECM), causando stenosi e ispessimento della tunica intima o neointima. Diverse vie di 
segnalazione controllano l’infiammazione e lo stress ossidativo dei vasi, tra cui il sistema 
melanocortinico (MCS). Il MCS è un complesso sistema ormonale composto da: 5 recettori 
(MCR) associati a proteine G (GPCR), peptidi derivati dal processamento post-traduzionale del 
pro-ormone pro-opiomelanocortina (POMC), proteine ancillari e antagonisti endogeni. 
Questo sistema regola numerose e varie funzioni fisiologiche e risposte infiammatorie. 
Indagini precliniche indicano che l’attivazione di alcuni MCR, in particolare di MC1R, possa 
essere una nuova strategia per controllare le patologie infiammatorie.  Un MCS attivo è stato 
descritto a livello locale nelle cellule endoteliali (EC) del microcircolo cutaneo e celebrale 
umano. Nel topo, l’ormone melanotropo alpha (α-MSH) agendo sul MC1R endoteliale modula 
il tono arterioso aumentando il rilassamento vascolare indotto dall’ossido nitrico (NO). Inoltre, 
il trattamento con agonisti dei MCR previene lo sviluppo di disfunzione vascolare e attenua 
l’infiammazione a livello della placca in un modello murino di aterosclerosi. Ci siamo perciò 
proposti di indagare se anche le cellule endoteliali e muscolari del macrocircolo umano 
esprimessero i recettori melanocortinici e quali fossero le loro funzioni. 
Metodi: l’espressione dei componenti del MCS nelle cellule endoteliali (HAoEC) e muscolari 
(HAoSMC) umane aortiche è stata analizzata tramite real-time PCR (qRT-PCR), western blot 
(WB), immunocitochimica (ICC) e immunoistochimica (IHC). La concentrazione intracellulare 
di adenosina monofosfato ciclica (cAMP) è stata misurata con un saggio ELISA, mentre la 
concentrazione intracellulare di calcio nelle EC è stata analizzata tramite indicatori 
fluorescenti di calcio. La migrazione direzionale delle EC e  delle SMC è stata indagata con un 
saggio che valuta la chiusura del fronte cellulare; la trasmigrazione delle SMC verso un 
gradiete di chemoattraente (chemiotassi) è stata analizzata con un sistema transwell. 
Abbiamo studiato l’effetto sulla proliferazione misurando un intercalante fluorescente del 
DNA sintetizzato de novo. In seguito al trattamento con α-MSH, sono stati misurati i profili di 
espressione genica nel tempo nelle EC e SMC aortiche migranti, usando rispettivamente 
microarray e sequenziamento dell’RNA. I cambiamenti fenotipici delle cellule muscolari e i 
biomarcatori associati sono stati analizzati tramite ICC e qRT-PCR. 
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Risultati: Abbiamo mostrato che le cellule endoteliali e muscolari umane aortiche esprimono 
recettori melanocortinici funzionalmente attivi. Le EC esprimono MC1R ma non altri 
componenti del sistema melanocortinico, nè il precursore POMC. L’attivazione del recettore, 
tramite il ligando naturale α-MSH, accelera la migrazione delle EC in un saggio direzionale in 
vitro. Questo evento è associato ad un aumento intracellulare di calcio e all’ inibizione 
dell’aumento di cAMP. L’analisi dell’espressione genica nel tempo sulle EC migranti ha 
permesso di identificare una co-regolazione dinamica di geni coinvolti nell’interazione 
matrice-recettore, nel traffico di vescicole e nella sensibilià ai metalli, tutti processi che hanno 
una rinomata importanza nella migrazione delle EC. 
Le SMC esprimono MC1R e MC4R, ma non POMC. In vitro, il trattamento con α-MSH favorisce 
il differenziamento delle HAoSMC da un fenotipo sintetizzante ad un fenotipo contrattile. Il 
trattamento promuove un significativo allungamento morfologico delle cellule (picco d’effetto 
tra 6-12 ore) e un aumento dell’espressione genica e proteica di  α-smooth-muscle actin e 
smooth-muscle-22-α, marcatori del fenotipo contrattile. L’attivazione di MCR rallenta la 
migrazione delle SMC in un saggio di migrazione direzionale wound-healing (effetto massimo 
tra 9-12h) e in un saggio chemotattico. Abbiamo mostrato che MC1R è direttamente coinvolto 
nel processo di migrazione. Inibendo questo recettore con un antagonista specifico (MSG-606) 
si ristabilisce un normale livello di migrazione, cosa che non accade inibendo invece MC4R. 
Inoltre, l’attivazione di MCR diminuisce la proliferazione delle SMC. Abbiamo infine indagato 
le vie di segnalazione attivate a valle di MC1R nelle SMC migranti analizzando il trascrittoma e 
proteine specifiche. In particolare abbiamo riscontrato una modulazione negativa della via di 
segnalazione p38MAPK/HSF1 e una significativa riduzione della fosforilazione di p38MAPK  in 
seguito al trattamento con α-MSH. Tale via di segnalazione potrebbe essere il meccanismo di 
MC1R per il controllo della migrazione delle SMC. 
Conclusioni: questi risultati mostrano una nuova funzione dei recettori melanocortinici 
periferici, i.e. la regolazione della motilità delle EC e delle SMC e il mantenimento 
dell’omeostasi vascolare. Inoltre, questo è il primo studio che si propone di svelare il possibile 
coinvolgimento dei MCR, espressi a livello del macrocircolo, nella fisiopatologia del 
rimodellamento vascolare. Infatti, i risultati di questo studio suggeriscono i MCR come nuovi 
e promettenti target terapeutici per la prevenzione e il trattamento del rimodellamento 
vascolare patologico mediante il controllo dell’infiammazione vasale, della disfunzione 
endoteliale e dello switch fenotipico delle SMC. 
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The term vascular remodeling defines the structural changes in blood vessel geometry that 
occur in response to long-term physiologic alterations in blood flow or in response to vessel 
wall injury brought about by trauma or underlying cardiovascular diseases (CVDs) (Gibbons 
and Dzau 1994; Herity, Ward et al. 1999). The most common CVDs: hypertension, 
atherosclerosis, and post-angioplasty restenosis arise from maladaptive vascular remodeling 
characterized by inflammation, endothelial dysfunction, vascular smooth muscle cell 
alterations, and neointima formation. An estimated 17 million people die every year of CVDs, 
the primary cause of world death. The goal for health improvement is to identify new ways to 
treat CVDs. As a contribution to this objective, the specific interest of this thesis was to 
investigate the cardiovascular actions and mechanisms of melanocortins to identify and 
characterize new treatment targets and modalities to control maladaptive vascular 
remodeling. 
 
 The Melanocortin system  
The melanocortin system is an ancient hormonal modulatory system that appeared very early 
in evolution (Catania, Gatti et al. 2004). It is composed of peptides derived by the precursor 
prohormone proopiomelanocortin (POMC), five G-protein coupled receptors (GPCRs), specific 
antagonists and ancillary proteins. 
POMC is mainly expressed in the corticotrophs and melanotrophs of the anterior and 
intermediate lobes of the pituitary gland. In addition, it is found in other parts of the central 
nervous system (CNS), including the arcuate nucleus of the hypothalamus and nucleus of the 
solitary tract, and in peripheral tissues such as the skin, pancreas, gastrointestinal tract, 
kidney, and liver (Smith and Funder 1988). The POMC gene encodes a protein precursor that 
generates bioactive peptides, including adrenocorticotropic hormone (ACTH), α-, β-, and γ-
melanocyte stimulating hormone (α-MSH, β-MSH, and γ-MSH) and β-endorphin, via several 
post-translational modification processes (Takahashi and Mizusawa 2013). Specific enzymes, 
the pro-hormone convertases, PC1/3, and PC2, make post-translational processing of POMC. 
In the anterior pituitary, POMC is cleaved by the PC1/3 into ACTH, β-LPH, and an N-terminal 
fragment. In the intermediate lobe and in the hypothalamus, POMC is more extensively 
processed by PC2 to produce α-MSH and CLIP from ACTH, and γ-MSH from the N-terminal 
fragment (Takahashi and Mizusawa 2013; Wolf Horrell, Boulanger et al. 2016) (Figure 1). Once 
produced, α-MSH undergoes a maturation process: α-MSH is N-acetylated by an unidentified 
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N-acetyltransferase. This acetylation stabilizes α-MSH against proteolytic degradation and 
prolongs its biological activity. Nevertheless, the half-life of α-MSH is very short since it is still 
rapidly metabolized (Catania, Gatti et al. 2004). 
  
Figure 1. POMC processing (Wolf Horrell, Boulanger et al. 2016). 
 
According to the current understanding, the pituitary gland releases POMC-derived peptides 
into circulation. The melanocortin peptides reach the peripheral tissues and function in an 
autocrine or paracrine manner on local melanocortin receptors (Cawley, Li et al. 2016). 
The melanocortin system also has two endogenous antagonists, Agouti signaling protein 
(ASIP) and Agouti-related protein (AgRP); no inhibitory proteins have been identified for any 
of the seven-transmembrane GPCR family. ASIP and AgRP are paracrine-signaling molecules, 
which bind to the melanocortin receptors (MCRs) with different affinities. They act as 
competitive antagonists and finely regulate receptors activities. Binding of ASIP and α-MSH to 
MC1R are mutually exclusive (Ollmann, Lamoreux et al. 1998). In addition, ASIP functions as 
an inverse agonist to decrease basal MC1R signaling (Lu, Willard et al. 1994) working with two 
major accessory proteins: attractin and mahogunin. Attractin is encoded by the Atrn gene, is 
a large single transmembrane protein with an ectodomain that binds the amino terminus of 
ASIP while Mahogunin is encoded by the Mgrn1 gene, and is an intracellular protein. 
Mutations in these ancillary proteins are associated with variations in pigmentation (He, 
Eldridge et al. 2003). AgRP is an orexigenic neuropeptide that is synthesized in the arcuate 
nucleus of the hypothalamus in the brain and acts as an endogenous antagonist of the MC3R 
and MC4R. Additionally, it has been demonstrated that AgRP is an inverse agonist of MC4R 
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that suppress basal cyclic adenosine mono-phosphate (cAMP) generation (Wilczynski, Joseph 
et al. 2005). 
 
 The Melanocortin receptors (MCRs)  
Five different MCRs have been cloned and characterized; all the MCRs have seven trans-
membrane domain, are coupled to adenylate cyclase and belong to the superfamily of GPCRs 
(Gantz, Miwa et al. 1993). The MCRs are the product of small genes, many of which are 
polymorphic. They show high sequence homologies, ranging from 60% identity between 
MC4R and MC5R to 38% identity between MC2R and MC4R (Catania, Gatti et al. 2004; Yang 
2011). Melanocortin receptors are the smallest GPCRs known, with short amino- and carboxyl-
terminal ends and a very small second extracellular loop. Human melanocortin receptors also 
lack several features found in most GPCRs: one, or two, cysteine residues in the first and 
second extracellular loops and prolines found in the fourth and fifth transmembrane (TM) 
domains. The melanocortin receptors contain conserved cysteine residues at a different 
region of the receptor, including cysteine residues within extracellular loops (ELs) and cysteine 
residues within TMs, and a cysteine residue in C terminus. Functional studies indicate that 
cysteines in EL3 may form a disulfide bond which is crucial for receptor function while cysteine 
residues in TMs of the human melanocortin receptors may have different roles in receptor 
expression, ligand binding and receptor activation (Yang 2011; Herraiz, Garcia-Borron et al. 
2017) (Figure 2).  
 
Figure 2. Amino acid sequence, coding sequence polymorphisms and possible arrangement of transmembrane 
regions in MC1R isoforms. Polymorphic positions for which no reliable association studies are available are 
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indicated in blue. Positions of R and r variants are shown in red and orange, respectively. Residues shown in gray 
correspond to indels and black circles with white lettering followed by broken arrows to premature stop codons. 
Positions, where both an indel and a point mutation have been found, are shown as blue circles hatched in white. 
(modified from (Herraiz, Garcia-Borron et al. 2017) 
 
MCRs can alternatively couple to the stimulatory G protein (Gs), or other G proteins (Gi/o, and 
Gq). MCRs associated to adenylyl cyclase in a Gs-mediated stimulatory fashion lead to an 
increase in cAMP production, activation of protein kinase A (PKA) and cAMP response 
element-binding (CREB) phosphorylation. However, melanocortin signaling is also associated 
with other cAMP-independent pathways such as the Ca2+/diacylglycerol/inositol trisphosphate 
(IP3) pathways (Eves, Haycock et al. 2003; Elliott, Szabo et al. 2004; Catania, Lonati et al. 2010). 
Pharmacological inhibition of the cAMP pathway using agents such as N6-phenylisopropyl 
adenosine caused a-MSH induction of an acute intracellular calcium signal. MCR signaling has 
also been associated with activation of the MAP kinase (Englaro, Rezzonico et al. 1995), Janus 
kinase/signal transducer and activator of transcription (Buggy 1998), and protein kinases C 
(PKC) pathways (Kapas, Purbrick et al. 1995). Furthermore, MCRs may be regulated by 
phosphorylation since they have recognition sites for PKA and C. 
Receptors complexity is also increased by the fact that MCRs, as part of the GPCR family, are 
finely regulated in loco. Different responsiveness can occur via altered receptor density (up- 
or down-regulation), modifications of the receptor such as phosphorylation that diminishes 
receptor-G protein interaction (uncoupling), and trafficking of receptor away from G protein 
(sequestration/internalization) that enables either recycling of receptor to a responsive form 
or facilitates receptor loss by lysosomal degradation (Billington and Penn 2003). Moreover, 
melanocortin peptides selectively bind to an activate melanocortin receptors with different 
affinities (Butler, Girardet et al. 2017) controlling various functions, such as energy 
homeostasis, pigmentation, inflammation (Figure 3). 
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Figure 3. Melanocortin receptors, peptide affinities and mainly functions (Adapted by Butler, Girardet et al. 
2017). 
 
 MC1R 
The MC1R was the first of the melanocortin receptors to be cloned (Mountjoy, Robbins et al. 
1992). It was originally cloned from cDNA libraries and detected in melanoma cells. The 
expression level of the MC1R is relatively low in normal melanocytes but it becomes markedly 
upregulated upon transformation of melanocytes into malignant melanoma (Loir, Perez 
Sanchez et al. 1999). MC1R has a high affinity for α-MSH and ACTH, and is also expressed in 
keratinocyte, fibroblasts, immune cells (neutrophils, monocytes, dendritic cells, B-
lymphocytes), glial cells, and endothelial cells (Catania, Gatti et al. 2004). 
Like many other GPCRs, oligomerization of MC1R is functionally important to modulate the 
ligand binding, coupling efficiency, desensitization, and trafficking through the endoplasmic 
reticulum (Sanchez-Laorden, Sanchez-Mas et al. 2006; Wolf Horrell, Boulanger et al. 2016). 
Desensitization and internalization also represent major mechanisms whereby receptor 
function can be regulated (Pitcher, Freedman et al. 1998). MC1R undergoes homologous 
desensitization following short exposure to its positive agonist, α-MSH, in a PKA-independent 
and G protein-coupled receptor kinase (GRK) dependent manner. Following agonist 
stimulation, GRKs phosphorylate GPCRs resulting in receptor decoupling from the G protein 
and subsequent internalization (Wolf Horrell, Boulanger et al. 2016).  
Among the five MCRs identified, MC1R has the highest affinity for α-MSH. MC1R activation 
controls melanogenesis and has a crucial role in determining the balance between 
phaeomelanin (yellow) over eumelanin (brown/black) pigment production (Cone 2006). In 
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humans, recessive mutations within MC1R that render the receptor unresponsive to 
melanocortin stimulation result in a red hair phenotype (Rees 2003). MC1R has a crucial role 
also as a mediator of immune responses. MC1R stimulation elicits anti-inflammatory activities; 
reduce the production of pro-inflammatory cytokines while concomitantly increasing the 
production of anti-inflammatory cytokines (Bohm, Schiller et al. 2006). The MC1R is present 
also in the central nervous system but only in the periaqueductal gray matter of the midbrain. 
This central MC1R might have a role in pain modulation (Xia, Wikberg et al. 1995). 
In order to study the different receptor physiology and functions, super potent modified 
peptides selective and /or specific for all the subtypes have been developed. For example, 
acetylated NDP-MSH, also known as afamelanotide or Melanotan-I, is a synthetic analog of α-
MSH developed to increase the short half-life of the physiologic peptide. It is an agonist at 
melanocortin receptors with Ki values: 0.085, 0.4, 3.8 and 5.1nM for MC1, MC3, MC4, and 
MC5 receptors respectively. In comparison with α-MSH and the other natural melanotropins, 
it possesses better resistance to enzymatic breakdown and it was demonstrated to have 
prolonged and more potent activity (Sawyer, Sanfilippo et al. 1980). Among the specific 
agonists of MC1R, one of the most potent and selective developed in the last years is BMS-
470539. It worked as a full agonist of recombinant human MC1R with an EC50 of 16.8 nM and 
an intrinsic activity of 88% in a cAMP accumulation assay. It was shown that BMS-470539 
exhibited anti-inflammatory properties following ischemia-reperfusion in the vasculature and 
inhibited leukocyte trafficking (Kang, McIntyre et al. 2006). Among the specific antagonist, 
153N-6 and MSG 606 are the most used. The 153N-6 peptide is a putative alpha-MSH 
antagonist at melanocortin receptor subtypes. The 153N-6 peptide can competitively inhibit 
NDP-MSH binding from all the receptor subtypes. The relative potency order of 153N-6 for 
inhibiting NDP-MSH binding was MC1R (Ki 955 +/- 35.7nM) = MC4R (Ki 1151 +/- 106nM) > 
MC3R (Ki 3229 +/- 637nM) > MC5R (Ki 6286 +/- 462nM) (Chhajlani 1996). MSG 606 is a potent 
human MC1R antagonist (IC50 = 17nM) and it is a partial agonist at human MC3R and MC5R 
(EC50values are 59 and 1300nM, respectively). It was shown that MSG 606 exhibited binding 
affinity for A375 melanoma cells in vitro (Cai, Stankova et al. 2013) and reversed morphine-
induced hyperalgesia in female mice, with no effect in male mice (Arout, Caldwell et al. 2015).  
 MC2R 
The MC2R, unlike the other MCRs, bind only ACTH. It is expressed in the adrenal cortex zona 
reticularis and zona fasciculata, where it mediates the effects of ACTH on steroidogenesis and 
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steroid secretion. In addition to the adrenal gland, MC2R seems to be present in the white 
adipose tissue in mice but not in humans (Boston and Cone 1996), indicating that there are 
species differences in the expression profiles of the MC2R. 
 MC3R 
The MC3R is the only MCR that responds to stimulation with γ-MSH at physiological 
concentrations. Thus, γ-MSH seems to be the natural ligand. MC3R is expressed in the central 
nervous system as well as in multiple tissues in the periphery, including gut-intestinal tract, 
placenta, heart, kidney and immune cells (Catania, Gatti et al. 2004). 
 MC3R appears to participate in the modulation of autonomic functions, feeding, and 
inflammation (Abdel-Malek 2001; Getting, Allcock et al. 2001). α-MSH activation of MC3R and 
MC4R located in the medullary dorsal-vagal complex mediated hypotension and bradycardia 
(Li, Varga et al. 1996). MC3R-deficient mice showed an increased fat mass, reduced lean mass, 
and a higher ratio of weight gain to food intake suggesting the participation of MC3R in energy 
homeostasis (Chen, Marsh et al. 2000). MC3R activation mediates the protective influences of 
melanocortins in myocardial ischemia/reperfusion-induced arrhythmias in rats (Guarini, 
Schioth et al. 2002). Furthermore, activation of MC3R has clear anti-inflammatory influences 
(Getting and Perretti 2000; Getting, Christian et al. 2002). 
 MC4R 
The human MC4R was the second neural MCR to be cloned. Alignment of MC4R with other 
MCRs showed that it has the highest homology with the MC3R, with 58% identity and 76% 
similarity. The order of potency for activation of MC4R is α-MSH > ACTH > β-MSH >> γ-MSH. 
MC4R is mainly expressed in the CNS where it has a very wide distribution, including the 
cortex, thalamus, hypothalamus, brain stem and spinal cord (Mountjoy, Mortrud et al. 1994). 
Distribution of MC4R is consistent with its involvement in autonomic and neuroendocrine 
functions (Catania, Gatti et al. 2004). In addition, the MC4R mRNA is also expressed in 
peripheral tissues during the fetal period, including the developing heart (E14), lung (E16), 
muscles involved in respiration such as diaphragm and intercostal muscle (E14), as well as 
other muscles (Mountjoy, Jenny Wu et al. 2003; Tao 2010) . The potential physiological 
functions of the MC4R in these organs remain to be elucidated. 
MC4R regulates food intake and energy homeostasis. Knock out mice for MC4R show 
maturity-onset obesity, with hyperphagia, hyperinsulinemia, and hyperglycinemia (Tao 2010). 
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Accordingly, the pharmaceutical industry is looking at MC4R as a target to treat weight 
disorders. This receptor has been associated with several physiological functions, including 
sexual function and pain, but the most important role for MC4R is certainly in the control of 
energy balance and cardiovascular functions. 
To study the receptor functions specifically, selective agonists and antagonists have been 
developed. JKC 363 is a potent and selective MC4R antagonist (IC50 values are 0.5 and 44.9nM 
at MC4R and MC3R respectively) that contrapose the effects of α-MSH. It suppresses 
thyrotropin-releasing hormone release (Kim, Small et al. 2002), attenuates food intake (Verty, 
McFarlane et al. 2004) and reduces formalin-induced pain in vivo (Bellasio, Nicolussi et al. 
2003). PG 931, instead, is a potent and selective MC4R agonist (IC50 values are 0.58 and 55nM 
for human MC4R and MC3R respectively). It was shown that it produced a rapid and dose-
dependent restoration of cardiovascular and respiratory function in hemorrhage-shocked rats 
(Grieco, Balse-Srinivasan et al. 2003; Giuliani, Mioni et al. 2007).  
 MC5R 
MC5R is similar to the MC1R and MC4R in its capacity to recognize α-MSH and ACTH but not 
γ-MSH (α-MSH > ACTH >> γ-MSH)(Catania, Gatti et al. 2004). The MC5R was the last of the 
MCR gene family to be cloned by homology screening from genomic DNA in man (Chhajlani, 
Muceniece et al. 1993), mouse (Labbe, Desarnaud et al. 1994), and rat (Griffon, Mignon et al. 
1994). 
MC5R is a relatively ubiquitous receptor in peripheral tissues but it is widely expressed in the 
secretory epithelia of many exocrine glands such as the adrenal, lacrimal and sebaceous 
glands (Chhajlani 1996; Catania, Gatti et al. 2004). This kind of distribution indicates that MC5R 
is involved in regulating the synthesis and secretion of exocrine gland products (Chen, Kelly et 
al. 1997). However, data also indicate immunomodulatory functions in B and T lymphocytes 
and in mast cell lines (Buggy 1998; Taylor and Lee 2011). 
 
 Vascular structure and homeostasis  
The vascular system of the human body is comprised of arteries, capillaries, and veins that 
contribute to cellular function, absorption of essential nutrients, and removal of cellular and 
metabolic waste products maintaining the cell homeostasis. The arteries and veins structure 
(Figure 4) is similar and composed of three layers. Each layer exhibits specific histologic, 
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biochemical and functional characteristics to maintain vascular homeostasis and to regulate 
the vascular response to stress or injury. The Tunica intima is composed of epithelial and 
connective tissue. The specialized monolayer of epithelium (the endothelium), is responsible 
for creating an interface between the blood and tissues and plays a role in blood vessel dilation 
and constriction. Next to the endothelium is the basement membrane or basal lamina that 
binds the endothelium to the connective tissue. The basement membrane provides strength 
while maintaining flexibility and it is permeable. The middle layer, Tunica media is the thickest 
layer in arteries and consists of smooth muscle cells arranged in circular sheets supported by 
connective tissue, primarily made up of elastic fiber. The outer tunica, the tunica externa or 
adventitia, is a substantial sheath of connective tissue composed primarily of collagenous 
fibers that exert protective functions. 
 
 Figure 4. Vascular structure (adapted from Fortier A. et al.2014) 
 
 Endothelial cell  
The endothelium is the main regulator of vascular wall homeostasis. Physiologically, 
endothelial cells maintain a relaxed vascular tone and low levels of oxidative stress by 
releasing mediators such as nitric oxide, prostacyclin and endothelin, and controlling local 
angiotensin-II activity. The endothelium also actively regulates vascular permeability to 
plasma constituents, platelet and leukocyte adhesion and aggregation, and thrombosis (Sitia, 
Tomasoni et al. 2010). 
However, a number of conditions altered the endothelial regulation of blood vessel function. 
In response to a variety of noxious stimuli, the endothelium undergoes phenotypical 
modulation to a non-adaptive state known as “endothelial dysfunction”, which is 
characterized by the loss or dysregulation of the homeostatic mechanisms that operate in 
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healthy endothelial cells (Pepine 1998; Della Rocca and Pepine 2010). This pathophysiological 
condition is associated with the increased expression of adhesion molecules, an increased 
synthesis of pro-inflammatory and pro-thrombotic factors, increased oxidative stress, and the 
abnormal modulation of vascular tone, all of which may lead to functional manifestations 
including impaired endothelium-dependent vasodilation. Depending on the pathology, 
vascular bed and the presence of other risk factors such as diabetes and obesity, the 
mechanisms underlying endothelial dysfunction may be multifactorial and considerably 
different from each other (Sitia, Tomasoni et al. 2010). Current evidence suggests that 
endothelial dysfunction occurs early in the process of atherogenesis, and contributes to the 
formation, progression, and complications of atherosclerotic plaque (Figure 6). 
In hypertensive vessels and in the first steps of atherosclerosis progression, the expression of 
eNOS enzyme by the endothelium is paradoxically increased, indicating that the ability of 
eNOS to produce NO has become compromised and/or the bioavailability of NO has declined 
(Harrison 1997; Gimbrone and Garcia-Cardena 2016). Reduced NO bioavailability can arise 
from attenuated production but also from the increased breakdown of NO by reactive oxygen 
species. Thus, oxidative stress is one of the main mechanisms contributing to endothelial 
dysfunction (Touyz and Briones 2011). Finally, in healthy arteries, the endothelium serves as 
non-adhesive and anti-thrombotic surface thereby providing vascular protection. Since 
endothelium-derived vasodilator substances exert anti-thrombotic and anti-proliferative 
actions and contribute significantly to the protective role of endothelium in vascular 
homeostasis, an impairment of endothelium-dependent vasodilatation is often accompanied 
by dysregulation of endothelial-blood cell-interaction, which may lead to inflammation, 
vascular lesions, and thrombosis.  
When the balance between EC NO production and oxidant stress is disrupted, ECs become 
dysfunctional. Vascular SMC relaxation is impaired and its phenotype switches to a synthetic 
form that promotes growth, proinflammatory responses, and thrombotic activities. 
Eventually, these functional defects result in structural damage to the arterial wall with SMC 
migration and proliferation in the media and sub-intima, creating favorable conditions for 
platelet and leukocyte activation and adhesion as well as cytokines that increase permeability 
to oxidized lipoproteins and inflammation mediators. Hence, endothelial dysfunction leads to 
adaptive vascular remodeling and it is pivotal to atherogenesis. It is present at the earliest 
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stages as well as later stages of the arterial disease, contributing to clinical outcomes related 
to tissue damage (ischemia, infarction, and organ failure) (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Atherosclerosis timeline, showing the underlying role of endothelial dysfunction in the progression of 
atherosclerosis from the initial lesion to the complicated lesion (Della Rocca and Pepine 2010). 
 
 Endothelial cell migration  
Endothelial cells migrate during vasculogenesis and angiogenesis, but also in a damaged vessel 
to restore vessel integrity. Artery endothelial dysfunction and/or injury are linked to the 
pathogenesis of atherosclerosis, thrombosis, or surgery procedure complications (Otsuka, 
Finn et al. 2012). An essential biological process involved in endothelial healing upon vascular 
injury is EC migration. When a blood vessel is damaged, the restoration of endothelium and 
vessel integrity is achieved through migration of healthy ECs to the site of the lesion and 
subsequent proliferation. Hence, EC migration has a key role, besides angiogenesis, in vascular 
repair and tissue regeneration (Michaelis 2014; Hasan and Siekmann 2015). Understanding 
and accelerating the mechanisms of endothelial wound healing is of fundamental interest for 
biotechnology and of significant medical utility in repairing pathologic changes to the 
vasculature induced by invasive medical intervention.  
 Endothelial cell migration is a mechanically integrated molecular process that involves 
changes in cell adhesion, signal transduction, and cytoskeletal organization. It involves three 
major mechanisms, namely chemotaxis, the directional migration toward a gradient of soluble 
chemoattractants; haptotaxis, the directional migration toward a gradient of immobilized 
ligands; and mechanotaxis, the directional migration generated by mechanical forces 
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(Michaelis 2014). Chemotaxis of endothelial cells is driven by growth factors such as vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor, whereas haptotaxis is 
associated with increased endothelial cell migration activated in response to integrins binding 
to extracellular matrix component. Mechanotaxis is because endothelial cells are constantly 
in contact with shear stress, which contributes to activate the migratory pathway. 
The migratory pathway identified in endothelial cells comprise migration initiation, filopodia 
and lamellipodia formation and cell polarization (Figure 7). 
Figure 7. A model of the polarized activation of signaling molecules during EC migration (Li, Huang et al. 2005). 
 
 Two important genetic pathways influencing these processes are the VEGF and the Notch 
signaling pathways that control angiogenesis (Michaelis 2014). The Serum response factor is 
an evolutionarily conserved transcription factor known to be important for filopodia 
formation, needed for cell movements (Franco, Blanc et al. 2013). Moreover, MAP4K4 seems 
to be essential in the retraction of the plasma membrane at the rear end that contrapose the 
extension of protrusions in the direction of cell migration (Vitorino, Yeung et al. 2015). Rac1, 
Cdc42 and RhoA control EC migration via changes in cytoskeletal arrangement regulating the 
formation of lamellipodia, filopodia and stress fibers (Li, Huang et al. 2005). Among these, the 
Calcium signaling pathway has essential roles in EC migration. Ca2+ is regulated spatially and 
temporally in migrating cells, driving polarization, protrusion, retraction, and adhesion at the 
22 
 
right place and right time. Cells create local Ca2+ pulses near the leading edge, maintain 
cytosolic Ca2+gradient from back to front, and restore Ca2+depletion for persistent cell motility 
(Tsai, Kuo et al. 2015). 
 
 Vascular Smooth Muscle Cell (SMC) 
Vascular smooth muscle cells are specialized cells, mainly located in the tunica media of blood 
vessels, responsible for contraction and relaxation to maintain blood pressure and blood flow 
distribution. SMCs within the adult blood vessel proliferate at an extremely low rate and 
exhibit a very low synthetic activity.  
SMCs express a unique repertoire of contractile proteins, ion channels, and signaling 
molecules required for the contractile function that is unique compared with other cell types 
and other muscle lineages including the skeletal muscle and cardiac muscle (Owens, Kumar et 
al. 2004). SMCs contraction occurs by Ca2+ /calmodulin phosphorylation of myosin light-chain 
kinases that phosphorylates myosin light chain. Phosphorylated myosin light chain form cross-
bridges with actin. Contraction is antagonized by myosin light-chain phosphatase, the activity 
of which is negatively regulated by Rho-kinase, PKC-dependent 17kDa C-protein-potentiated 
inhibitor of protein phosphatase, and positively regulated by endothelial cell-derived nitric 
oxide through soluble guanylate cyclase-cGMP-PKG. In vascular SMCs, intracellular Ca2+ 
concentrations may be increased, to induce contraction, by influx from outside the cell 
through voltage-gated calcium channels that activate upon cellular depolarization or from the 
sarcoplasmic reticulum by ryanodine or IP3 receptor channels. Either excitation-contraction 
coupling (i.e., action potentials) or pharmaco-mechanical coupling induce 
contraction/relaxation in SMCs (Misono, Philo et al. 2011). SMC responses are driven through 
the activation of membrane receptors, among which GPCRs are the most common. GPCRs are 
activated by endogenous agonists including hormones and neurotransmitters (prostaglandins, 
Angiotensin II, Adrenalin). Several GPCRs, such as the angiotensin II AT1 receptor, the 
endothelin-1 ETA receptor, and the α1 -adrenoceptor mainly use the Gq/11-PLC signaling 
pathway to stimulate vasoconstriction. Other receptors, such as the α2-adrenoceptor, 
mediate contraction via Gi/o proteins. Relaxation of vascular SMCs is mainly mediated by Gs 
protein-coupled receptors, which reduce the Ca2+ sensitivity (Maguire and Davenport, 2005). 
Unlike either skeletal or cardiac muscle cells that are terminally differentiated, SMCs within 
adult animals retain remarkable plasticity and can undergo rather profound and reversible 
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changes in phenotype in response to changes in the local environment (Owens, Kumar et al. 
2004) (Figure 8).  
Figure 8. The SMC phenotypic switch in response to the local environment (Owens, Kumar et al. 2004). 
 
To perform a diversity of functions, SMC phenotype spans a continuum from quiescent and 
contractile to proliferative and synthetic (Owens, Kumar et al. 2004; Beamish, He et al. 2010; 
Milewicz, Kwartler et al. 2010). The diversity between phenotypes becomes apparent in 
morphology, expression levels of SMC marker genes, proliferative potential and migration 
properties (Figure 9). Contractile SMCs have a fully functional contractile apparatus that 
responds to small molecule signals such as acetylcholine and norepinephrine. Contractile 
SMCs are characterized by an ultrastructure composed of myofilaments and minimal rough 
endoplasmic reticulum, Golgi, or free ribosomes. In culture, these cells possess a dense 
fusiform morphology. Synthetic SMCs have a fibroblast-like aspect, contain minimal 
contractile proteins and secrete ECM. The ultrastructure of these cells shows a cytoplasm 
devoid of contractile bundles with extensive rough endoplasmic reticulum, Golgi, and 
ribosomes. In culture, these cells adopt a spread, rhomboid shape, and then begin to grow 
over one another in a ‘‘hill-and-valley’’ morphology (Beamish, He et al. 2010; Milewicz, 
Kwartler et al. 2010). The synthetic phenotype is also correlated with SMC proliferation that 
increases from 3%–5% to 40%–60% during primary culture and pathologies such as intimal 
hyperplasia. Finally, synthetic SMCs show higher migratory activity than contractile SMCs 
(Rensen, Doevendans et al. 2007). 
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Figure 9. Main differences in SMCs phenotypes. (Milewicz, Kwartler et al. 2010) 
 
The expression patterns of a wide range of protein markers have been characterized to 
describe the phenotypic state of SMCs (Table 1). Contractile SMCs, which predominate in 
normal vessels, exhibit a mature contractile apparatus including α-SMA, smooth muscle 
myosin heavy chains (SM-MHC), MHY11, Calponin, SM22α, and Smoothelin. There also are 
several markers of synthetic SMC phenotype, such as Caldesmon, MHY10 (Smemb) and 
Vimentin, but these have been utilized less widely in the literature and generally, these 
markers have fewer SMC specificity. Markers that are upregulated in the synthetic phenotype 
are rare. Instead, the disappearance of proteins associated with the contractile phenotype is 
generally taken as characteristic of the synthetic phenotype (Rensen, Doevendans et al. 2007; 
Beamish, He et al. 2010). 
SMC plasticity is essential during vascular development when the SMCs play a key role in the 
morphogenesis of the blood vessel and exhibits high rates of proliferation, migration, and 
production of extracellular matrix components. Similarly, in response to vascular injury, the 
SMC dramatically increases its rate of cell proliferation, migration, and synthetic capacity and 
plays a critical role in vascular repair. However, SMC high plasticity could bring to adverse 
phenotypic switching and acquisition of characteristics that can contribute to the 
development and/or progression of vascular disease. Indeed, there is strong evidence that 
phenotypic switching of the SMC plays a major role in a number of human diseases including 
atherosclerosis, cancer, and hypertension (Bennett, Sinha et al. 2016). Extensively 
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proliferating SMCs play a pivotal role in restenosis that occurs after vascular procedures such 
as endarterectomy and percutaneous coronary intervention.  
Table 1. Characteristics of widely used SMC marker proteins (Rensen, Doevendans et al. 2007) 
 
 Smooth muscle cell proliferation and migration 
During vascular development, SMC migration is guided by chemotactic stimuli, such as 
platelet-derived growth factor (PDGF), in order to assure the correct vessels formation. 
Normal vessel formation occurs by formation of an endothelial cell tube followed by migration 
of pericytes or smooth muscle progenitor cells that differentiate to smooth muscles of the 
tunica media. In physiologic conditions, the vascular SMCs are in a non-proliferating and non-
migrating state, since there are not environmental pro-proliferating and migrating factors; 
moreover, focal adhesions and junctions between cells and extracellular matrix keep cells in 
place. Smooth muscle cell migration occurs not only during vascular development, but also in 
response to vascular injury, and during atherogenesis. Vascular injury occurs clinically after 
angioplasty, vascular stent implantation, or organ transplantation. In animal models of 
vascular injury, intimal and medial thickening is thought to be attributable to SMC 
proliferation as well as migration from media to intima (Zahradka, Harding et al. 2004; 
Gerthoffer 2007). In response to an inflammatory micro-environment, such as a vascular 
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lesion, vascular SMC proliferation and migration is induced to repair the injury; however if the 
stimulus is persistent, excessive ECM deposition lead to vessel thickening. In atherosclerosis, 
the vascular SMC contributes to vessel wall inflammation and lipoprotein retention, as well as 
to the formation of the fibrous cap that provides stability to the plaque.  
It has been observed that vascular SMC remodeling in vivo and in vitro begins with an 
extracellular stimulus that activates receptors located on the cell surface. These, in turn, 
transduce the external signal to several pathways, leading to a series of coordinated 
remodeling events that trigger cell migration, proliferation or both. Signaling pathways that 
are activated when exposed to mitogens, growth factors or peptides often trigger pathways 
that stimulate both proliferation and migration. The main factor that modulates proliferation 
is PDGF-BB that it is also a well-known pro-migratory chemotactic factor. Pro-migratory stimuli 
activate signal transduction cascades that trigger remodeling of the cytoskeleton, change the 
adhesiveness of the cell to the matrix, and activate motor protein (Gerthoffer 2007).  
The p38 MAPK cascade it is one of the main pathway implicated in SMC migration. A signaling 
cascade comprising MAPK kinase 3, p38 MAPKs, MAPK activated protein kinase 2 (MK2), and 
heat shock protein 27 (HSP27) is necessary for migration of both smooth muscle cells and 
endothelial cells. The p38 MAPK cascade is activated by numerous pro-migratory stimuli, 
including PDGF, angiotensin II, S1P, and thrombin. Chemical inhibitors of p38 MAPK block 
vascular remodeling in a rabbit injury model, although, interestingly, p38 MAPK inhibitions did 
not stop the migration of cultured cells. Inhibition of p38 MAPK also alters the reorientation 
of cultured SMC in response to stretch suggesting p38 MAPK and its targets are early sensors 
of both the chemical and mechanical milieu of the vessel wall. The effect of p38 MAPK 
inhibitors in vascular remodeling is likely to be a combination of effects on cell migration via 
inhibiting phosphorylation of HSP27 and actin remodeling, as well as effects on transcription 
and translation of proinflammatory mediators and proteins regulating the cell cycle (Wang, 
Castresana et al. 2004). 
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The p38 MAPK/MK2/HSP27 pathway in smooth muscle is associated with the control of actin 
filament polymerization and subsequently, cell migration (Salinthone, Tyagi et al. 2008). 
Hedges and colleagues in 1999 showed that activation of p38 MAPK leading to HSP27 
phosphorylation is necessary for migration of tracheal smooth muscle cells (Hedges, Dechert 
et al. 1999). Studies in airway smooth muscle showed the p38 MAPK signaling pathway 
mediates phosphorylation of HSP27 in response to serum, growth factors and cytokines 
(Hedges, Yamboliev et al. 1998). Blocking p38 MAPK activity with SB203580 inhibits activation 
of MK2, prevents phosphorylation of HSP27 and blocks smooth muscle cell migration (Hedges, 
Dechert et al. 1999). These studies established that activation of the p38 MAPK pathway by 
growth factors and pro-inflammatory cytokines promotes cell migration and that 
phosphorylation of HSP27 is necessary for migration. Subsequent investigations by other labs 
confirmed that the p38 MAPK/MK2/HSP27 pathway is necessary for migration of vascular 
smooth muscle cells (Lee, Lee et al. 2007), neutrophils (Jog, Jala et al. 2007), and fibroblasts 
(Hirano, Rees et al. 2004).  
Figure 10. Signaling pathways regulating HSP27 structure and function (Salinthone, Tyagi et al. 2008) 
 
Many, but not all, heat-inducible proteins contain heat shock response elements (HSE) in the 
5’ untranslated region of the coding sequence (Salinthone, Tyagi et al. 2008). Heat shock 
response elements are characterized by inverted repeats of nGAAn that are binding sites for 
transcription factors called heat shock factors (HSF). HSF-1 is the predominant mammalian 
HSF. Small HSP expression levels are probably controlled in smooth muscles by a combination 
of transcriptional regulation via heat shock factors, control of mRNA stability and regulation 
of translation. In many cells expression and phosphorylation of HSF-1 are regulated by stress 
signals to allow trimerization, binding to the heat shock response elements in the 5’ 
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untranslated regions of HSP genes and transcription of HSP mRNAs. Upstream of HSF-1, p38 
MAP kinases probably have important regulatory effects because HSP27 can be induced by 
vasoactive agents that activate the p38 MAPK cascade including thrombin, vasopressin and 
sphingosine 1-phosphate (Salinthone, Tyagi et al. 2008). Interestingly the p38 MAPK/MK2 
signaling cascade is also the pathway that promotes phosphorylation of HSP27, dissociation 
of HSP27 multimers and increased F-actin formation in actin cytoskeletal remodeling (Figure 
10). This suggests dual effects of p38 MAPK on both short-term events promoting HSP27 
phosphorylation and in longer-term processes promoting HSP27 expression. 
 
 Vascular remodeling 
Vascular remodeling is an active process of structural alteration that involves changes in at 
least four cellular processes: cell growth, cell death, cell migration, and production or 
degradation of extracellular matrix and is dependent on a dynamic interaction between locally 
generated growth factors, vasoactive substances, and hemodynamic stimuli. Remodeling is 
usually an adaptive process that occurs in response to long-term changes in hemodynamic 
conditions, but it may contribute to the pathophysiology of vascular diseases and circulatory 
disorders (Gibbons and Dzau 1994; Herity, Ward et al. 1999). Mechanisms involved in arterial 
remodeling include fibrosis, hyperplasia of the arterial intima and media, changes in vascular 
collagen and elastin, endothelial dysfunction, and arterial calcification. Migration and 
proliferation of vascular smooth muscle cells contribute to thickening of the intima. 
Differentiation of smooth muscle cells from their contractile to a secretory or osteogenic 
phenotype may lead to increased vascular tone and promotes extracellular matrix 
calcification.  
There are different types of remodeling. Arterial remodeling can be inward or outward and 
can be hypertrophic (thickening of the vascular wall), eutrophic (constant wall thickness), or 
hypotrophic (thinning of the vascular wall) (Mulvany, Baumbach et al. 1996) (Figure 11).  
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Figure 11. Different types of vascular remodeling (van Varik, Rennenberg et al. 2012) 
 
Hypotrophic remodeling results in a relatively thinner wall and a lower wall-to-lumen ratio. 
Conversely, hypertrophic remodeling is characterized by thickening of the vascular wall due 
to cellular hyperplasia and/or hypertrophy or deposition of extracellular matrix material and 
results in increased wall-to-lumen ratio. When the diameter of the vessel changes but the 
wall-to-lumen ratio remains the same it is called eutrophic remodeling (van Varik, Rennenberg 
et al. 2012).  
The features of vascular remodeling, intimal hyperplasia, medial hypertrophy, hyperplasia of 
vascular SMCs, and deposition of ECM, cause thickening of the arterial wall that reduces 
tensile stress. Vascular adult SMCs synthesize non-elastic collagen causing the stiffening of the 
vascular wall (Greenwald 2007) that it is increased also by degradation of ECM and the 
deposition of calcium minerals. In addition to structural changes, endothelial function plays 
an important role in arterial remodeling. Blood flow and shear stress stimulate endothelial 
cells to produce nitric oxide, which in turn influences contraction and relaxation of vascular 
SMCs. Endothelial function decreases with age and endothelial dysfunction is common in 
many cardiovascular diseases. Moreover, in response to pathological conditions, such as 
altered shear stress or inflammation, endothelial cells produce cytokines and growth factors 
that influence the homeostasis of the vascular wall (van Varik, Rennenberg et al. 2012). 
SMC proliferation and migration are hallmarks in maladaptive vascular remodeling, cause 
neointima formation and promote atherosclerosis. Although the benefit/risk of therapeutic 
inhibition of vascular SMC proliferation in atherosclerosis is unclear, experimental and human 
evidence prompts the use of anti-proliferative therapy for in-stent restenosis, bypass graft 
failure and other vascular proliferative disorders (Dzau, Braun-Dullaeus et al. 2002).  
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Stent implantation has become a widely used procedure to treat vessel occlusion but it is not 
without complications. Restenosis or the re-narrowing of the arteries are the principal adverse 
events. In-stent restenosis occurs in 15–20% of patients receiving a bare metal stent for the 
treatment of simply coronary lesions but may occur in up to 30–60% of patients with complex 
lesions (Puranik, Dawson et al. 2013). To prevent restenosis and pathological vascular 
remodeling has been developed drug-eluting stents (DES). The first generation DES are 
covered with potent anti-proliferative agents such as Sirolimus and Paclitaxel. Second 
generation stents bring compound more specific, more efficacious and selective anti-
proliferative agents that have lower systemic toxicity and do not delay endothelial healing 
such as Everolimus and Zotarolimus (Byrne, Joner et al. 2015). Furthermore, DES placement is 
not feasible for alleviating the restenotic response in bypass grafts, transplants, or 
hemodialysis grafts, and there have been reports of increased risk of late stent thrombosis 
(Puranik, Dawson et al. 2013). The drug that covers the second-generation stents have anti-
proliferative activity and block SMC proliferation, with the secondary adverse event due to 
the decrease in endothelial proliferation and wound closure. In order to develop better-
targeted therapies, with a decreased risk of stent-induced thrombosis, a better understanding 
of the pathogenesis of endothelial dysfunction and neointimal hyperplasia is required. A 
better strategy could be the development of new drugs able to control SMC migration and 
proliferation without affecting EC functions. 
 
 Involvement of MCRs in inflammation and cardiovascular 
functions 
Preclinical investigations indicate that activation of certain MCR subtypes, primarily MC1R, 
could be a novel strategy to control inflammatory disorders (Catania, Gatti et al. 2004). The 
anti-inflammatory influences of α-MSH, the prototypic melanocortin, are exerted through 
inhibition of inflammatory mediator production and reduction of inflammatory cell migration. 
Melanocortin peptides exert anti-cytokine and anti-inflammatory effects in blood cells, cells 
of the immune system, and in other cell types including neural, endothelial, and epithelial cells 
(Lipton and Catania 1997). Moreover, α-MSH is able to inhibit activation of the nuclear factor-
kB (NF-kB) (Manna and Aggarwal 1998), an essential transcription factor expressed in all 
eukaryotic cells that induces transcription of many molecules involved in the inflammatory 
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process. It is also known that α-MSH produced within the brain inhibit fever (Lipton, Macaluso 
et al. 1991), so that peptide could act centrally to modulate inflammation in the periphery. 
Nevertheless, the peripheral effects of locally expressed melanocortin peptides are poorly 
described.  
Interestingly, a local melanocortin system has been described in endothelial cells of the 
cutaneous (Hartmeyer, Scholzen et al. 1997) and cerebral (de Angelis, Sahm et al. 1995) 
microcirculation. Hartmeyer and colleagues showed that human dermal microvascular 
endothelial cells (HDMEC), as well as transformed human dermal microvascular endothelial 
cells (HMEC-1), expressed functionally active MC1R. The MC1R expression is upregulated 
upon stimulation with α-MSH that also increase IL-8 release. This study provides evidence of 
a local melanocortin system involved in the control of inflammation and leukocyte-endothelial 
cell interaction (Hartmeyer, Scholzen et al. 1997).  
There is increasing evidence demonstrating that the melanocortin system is crucially involved 
in cardiovascular regulation and atherosclerosis. α-MSH has been shown to modulate blood 
vessel tone by enhancing nitric oxide-cGMP dependent relaxation responses through 
endothelial MC1R in mice (Rinne, Nordlund et al. 2013). Moreover, in vivo treatment with α-
MSH analogs ameliorates endothelial dysfunction in aged and obese mice. Interestingly, 
treatment with MCR agonists was able to prevent the development of vascular dysfunction 
and attenuate plaque inflammation in pre-established atherosclerosis in a model of 
LDLR−/−ApoB100/100 mice (Rinne, Silvola et al. 2014). These studies suggested that the anti-
inflammatory and vasoactive effects of melanocortins could be therapeutically expanded to 
chronic inflammatory diseases such as atherosclerosis. 
The last studies about melanocortin implication in vascular pathologies showed that 
deficiency in MC1R signaling predisposes to vascular endothelial dysfunction and increased 
arterial stiffness in mice and humans (Rinne, Ahola-Olli et al. 2015). Moreover, using a cross 
model of Apoe-/- mice with recessive yellow (Mc1re/e) mice, carrying dysfunctional MC1R, 
Rinne and colleagues demonstrated that lacking in MC1R signaling accelerates diet-induced 
atherosclerosis (Rinne, Kadiri et al. 2018). They also showed that MC1R deficiency was 
associated with less collagen and smooth muscle cells, enhanced arterial accumulation of 
monocytes and macrophages and increased necrotic core, all indication of more vulnerable 
lesions. Finally, MC1R deficiency exacerbates HFD-induced hypercholesterolemia and hepatic 
lipid accumulation in Apoe −/− mice (Rinne, Kadiri et al. 2018). Accordingly, melanocortin 
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overexpression limits diet-induced inflammation and atherosclerosis in LDLR-/- mice 
(Nuutinen, Ailanen et al. 2018). Transgenic mice overexpressing MSH (MSH-OE) had improved 
glucose tolerance and limited atherosclerotic plaque formation, particularly after Western 
diet feeding. In terms of aortic vasoreactivity, MSH-OE blunted alpha1-adrenoceptor-
mediated vasoconstriction and enhanced relaxation response to acetylcholine, indicating 
improved endothelial function. In addition, MSH-OE markedly attenuated Western diet-
induced upregulation of proinflammatory cytokines (Ccl2, Ccl5, and Il6) that contribute to the 
pathogenesis of atherosclerosis (Nuutinen, Ailanen et al. 2018).  
No data of an active local melanocortin system in human macro-circulation have been 
reported yet. 
 
 Role of the melanocortin system in cell proliferation and migration  
The melanocortin system regulates migration and proliferation of different cell types, such as 
inflammatory cells, melanocytes, and melanoma cells, mainly by inhibiting them. 
Pro-inflammatory cytokines, such as IL-1 and TNF-α, induce the expression of adhesion 
molecules (ICAM, VCAM, integrins, and E-selectin) on the endothelium, promoting monocyte 
diapedesis from vessels to peripheral tissues. α-MSH controls monocyte migration by 
downregulating the expression of adhesion molecules and regulating IL-8 and Gro-α secretion 
on human dermal endothelium through MC1R (Kalden, Scholzen et al. 1999). Consistently, α-
MSH reduces T-lymphocytes (Cooper, Robinson et al. 2005), neutrophils (Catania, Gatti et al. 
2004), and eosinophils (Raap, Brzoska et al. 2003) proliferation and migration.α-MSH and 
ACTH control melanocyte migration and have mitogenic and melanogenic effects (Swope, 
Jameson et al. 2012). On the contrary, melanoma cells overexpress MC1R and treatment with 
α-MSH in vitro slows down migration, opposing the effect of TNF-α (Zhu, Lalla et al. 2004). 
These studies indicate the involvement of the melanocortin system in the regulation of cell 
proliferation and migration in both physiologic and pathologic conditions.  
EC and SMC proliferation and migration are hallmarks in vascular remodeling, neointima 
formation and atherosclerosis. The presence and implication of an active melanocortin system 
in human macrocirculation to control and prevent such processes that lead to cardiovascular 
diseases have never been studied yet. 
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HYPOTHESIS AND AIMS 
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We hypothesized that human macrovascular arteries express a local melanocortin system that 
could have a role in vessel homeostasis and in preventing and/or healing vascular remodeling. 
The broader scope of this study was to identify new therapeutic targets to control maladaptive 
vascular remodeling. 
 
The specific aims of the study were: 
• To investigate whether human macrovascular endothelial cells (ECs) and vascular 
smooth muscle cells (SMCs) express any MCRs and/or other melanocortin system 
components  
• To assess the in vitro effects of MCRs activation, and the underlying molecular 
mechanisms, on (1) aortic EC proliferation and migration and (2) aortic SMC 
proliferation, migration, and phenotypic switching 
• To validate in human tissues the expression and localization of the MCRs. 
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MATERIALS AND METHODS 
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 Experimental plan 
Vascular remodeling is a complex process that involves different cell types, i.e. 
endothelial cells (ECs), smooth muscle cells (SMCs) and inflammatory cells. An injury in 
the endothelium leads to inflammatory process and SMC activation. EC migration rate 
and proliferation are essential features in repairing the vessel wall. SMC phenotypic 
switch, migration and proliferation contribute to vessel thickening and neointima 
formation. We tested all these processes by appropriate in vitro techniques that 
mimicked cell behaviors in vivo during vessel remodeling. 
 Expression of MCS components in primary human aortic (HAoEC), coronary ECs 
(HCAEC) and human aortic smooth muscle cells (HAoSMC) were assessed by real-time 
PCR (qRT-PCR), Digital PCR (dPCR), western blot (WB), immunocytochemistry (ICC) and 
immunohistochemistry (IHC).  
 To test whether the receptors are functional, intracellular cyclic adenosine-mono-
phosphate (cAMP) concentrations were measured by  ELISA. 
 We tested the effects of MCR activation on EC migration with a gap closure assay and 
on EC proliferation measuring the ki67 expression by ICC.  We then analyzed the 
pathways downstream MCR activation in migrating HAoECs by measuring intracellular 
EC Ca2+ concentrations, using a fluorescent Ca2+ indicator, and by genome-wide, time-
dependent gene expression profiling, using microarrays. 
 We assessed the effects of MCR activation on SMC migration by a gap-closure 
migration assay and a transwell migration assays along a chemoattractant gradient. 
We measured proliferation of SMCs by incorporation of a nucleoside analog in newly 
synthesized DNA. SMC phenotypic changes and associated biomarkers were visualized 
and measured by ICC and Real-Time PCR. Genome-wide gene expression profiling was 
performed in migrating HAoSMCs after stimulation with α-MSH in time-course 
experiments, using RNA sequencing. We finally tested the modulation of the p38 
MAPK/HSF1 pathway, measuring p38 MAPK phosphorylation by WB. 
 
 Human primary cells 
Human Aortic Endothelial cells (HAoECs) were purchased from ECACC (Salisbury, UK), Lonza 
(Allendale, NJ), and Promocell (Heidelberg, Germany). We obtained three adults HAoECs and 
37 
 
recoded them as c1 (from ECACC), c2 (Lonza), and c3 (Promocell). Likewise, we obtained three 
adult HCAECs and recoded them as c4 (from ECACC), c5 (Lonza), and c6 (Promocell). ECs were 
cultured following manufacturers’ instructions. Cells were seeded in 75 mL plastic flasks 
(Corning, Tewksbury, MA) at a density of 2.5 × 103 cells/cm2 in EGM Endothelial cells growth 
media (Lonza, Belgium). We purchased Human Aortic Smooth muscle cells (HAoSMC) from 
ECACC (Salisbury, UK) and we cultured them following manufacturers’ instructions. Cells were 
seeded in 75 mL plastic flasks (Corning, Tewksbury, MA) at a density of 2.5 × 103 cells/cm2 in 
SmGM-2 Smooth Muscle Growth Medium-2 (Lonza, Belgium). We performed all experiments 
at cell passages 4–7. 
 Chemicals 
α-MSH was obtained from Phoenix Pharmaceuticals (Burlingame, CA); isobutyl 
methylxanthine (IBMX), PD0332991 isethionate, Thapsigargin, and Forskolin from Sigma-
Aldrich (St. Louis, MO). The peptide 153N-6 (H-[Met5, Pro6, D-Phe7, D-Trp9, Phe10]-MSH(5-13)) 
was bought from Bachem (Bubendorf, Switzerland), the peptide MSG 606, and JKC 363 from 
Tocris Bioscience (Bristol, UK). α-MSH, 153N-6, MSG 606 and JKC 363 were dissolved in water; 
IBMX, PD0332991, thapsigargin, and Forskolin in dimethyl sulfoxide (DMSO). 
 Genomic DNA sequencing 
We used a 3500 Genetic Analyzer (Applied Biosystems) to perform DNA sequencing of MC1R 
gene ORF for all the cells type. Genomic DNA amplicons of the MC1R ORF were produced by 
PCR with the following primers: MC1R_Forward(1) (-25) 5’-TCCTTCCTGCTTCCTGGACA-3’, 
MC1R_Reverse(1)(+980) 5’-CACACTTAAAGCCGCGTGCAC-3’. The amplified fragments were 
purified using the Agencourt AMPure XP kit (Beckman Coulter). Sequencing reactions were 
carried out using the BigDye Terminator v3.1 Kit (Applied Biosystems) in both strand directions 
to allow the production of four overlapping fragments. Sequencing primers used were the 
MC1R_Forward(1), MC1R_Reverse(1) and the inner MC1R_Forward(2) (+449) 5’-
TGCGCTACCACAGCATCGTG-3’ and MC1R_Reverse(2) (+510) 5’-CACCCAGATGGCCGCAAC-3’. 
Unincorporated fluorescent dideoxynucleotides and salts were removed with the BigDye 
XTerminator Purification Kit (Applied Biosystems). The purified sequencing reaction products 
were electrokinetically injected into a 50 cm Capillary Array filled with the POP-7 Polymer 
(Applied Biosystems). Electropherograms were analyzed by the Variant Reporter software 
v1.1 (Applied Biosystems). 
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 Real-time PCR 
Total RNA was extracted from ECs or SMCs, adding TRIzol Reagent (Invitrogen, Carlsbad, CA) 
directly to the culture dishes. Given that MCRs are single-exon intronless genes, we treated 
RNA samples with RNase-free DNase-I to eliminate genomic contamination and prevent 
amplification of genomic DNA. RNA quantification and purity assessment were performed by 
micro-volume spectrophotometry on an Infinite M200 PRO multimode microplate reader 
(Tecan, Männedorf, Switzerland). RNA quality and integrity were checked by microfluidics 
electrophoresis with the RNA 6000 Nano Assay Kit on a 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). 
Complementary DNA (cDNA) for single target gene expression analysis was synthesized from 
1μg of total RNA for each sample using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA). Real-time RT-PCR and single TaqMan Gene Expression 
Assays (Applied Biosystems) were used to assessing mRNA expression of the melanocortin 
receptors (MCRs), proopiomelanocortin (POMC), prohormone convertases, and SMC 
phenotypic markers, along with some reference genes as endogenous controls. Two replicates 
of each assay for each sample were run on a ViiA 7 Real-time PCR System (Applied Biosystems). 
Algorithms implemented in the ViiA 7 software v1.2 (Applied Biosystems) were utilized to 
impute experimental thresholds and baselines. 
 Digital PCR 
Digital PCR (dPCR) was performed on a QuantStudio™ 3D Digital PCR System platform 
composed by the QuantStudio™ 3D Instrument, the Dual Flat Block GeneAmp® PCR System 
9700 and the QuantStudio™ 3D Digital PCR Chip Loader (Life Technologies). dPCR was 
performed according to the manufacturer's instructions and the analysis was executed with 
QuantStudio® 3D Analysis Suite™ (Life Technologies). Primers labeled with FAM® dyes were 
used to evaluate the expression of target genes. 
 Antibodies 
Primary antibodies for WB and ICC were: anti-MC1R rabbit polyclonal (Alomone Labs, 
Jerusalem, Israel; supplied with the specific control peptide antigen), anti-MC4R rabbit 
polyclonal (Alomone Labs, Jerusalem, Israel; supplied with the specific control peptide 
antigen), anti-ATP1A1 antibody rabbit polyclonal (Cell Signaling Technology, Danvers, MA), 
anti-β-actin (AC-15) mouse monoclonal (Novus Biologicals, Littleton, CO), anti-Caveolin-1 
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mouse monoclonal (R&D research, Minneapolis, USA). Antibodies against phenotypic protein 
markers were anti-α-SMA mouse monoclonal (Dako, USA), and anti-SM22α rabbit polyclonal 
(Abcam, UK). Antibody to measure cell proliferation was anti-Ki67 rabbit polyclonal (Abcam, 
Cambridge, UK). Antibodies to analyze the pathways were anti p38MAPK rabbit monoclonal 
(R&D research, Minneapolis, USA) and anti-phospho-p38MAPK (R&D research, Minneapolis, 
USA). Secondary antibodies for immunoblotting were donkey anti-rabbit and anti-mouse IgG 
conjugated, respectively, to IRDye 800CW and IRDye 680RD infrared dyes (LI-COR Biosciences, 
Lincoln, NE). Secondary antibodies for immunocytochemistry were donkey anti-mouse and 
anti-rabbit IgG conjugated to DyLight 649 or DyLight 594 fluorochromes (Jackson 
ImmunoResearch Laboratories, West Grove, PA).  
 Immunoblotting 
HAoECs and HAoSMCs (1.2 × 106) were lysed in Milliplex MAP Lysis buffer (Millipore) with a 
complete protease inhibitor cocktail (Roche, Mannheim, Germany) to obtain whole extracts, 
or with the FractionPREP Cell Fractionation Kit (BioVision, Milpitas, CA) to obtain plasma 
membrane extracts. Proteins were quantified using the Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific). Thirty micrograms of each protein extract were mixed with the Novex Tris-
Glycine SDS sample buffer 2× and the Novex sample reducing agent 10× (Invitrogen). Samples 
were loaded onto 4-12% gradient Novex WedgeWell precast Tris-Glycine polyacrylamide gels 
(Invitrogen) and run in Novex Tris-Glycine SDS running buffer for 40 min at 200 V. Samples 
were blotted on nitrocellulose membranes using an iBlot system (Invitrogen). Membranes 
were blocked in the Odyssey blocking buffer (LI-COR Biosciences) for 1 h. Pre-absorption was 
performed by incubating the anti-MC1R and MC4R antibodies for 30 min at room temperature 
with the inhibitory MC1R or MC4R peptide, respectively (two-fold excess of the peptide by 
weight). Primary or the pre-absorbed antibodies were diluted (1:1000) in the Odyssey blocking 
buffer (LI-COR Biosciences), and membranes were incubated overnight at 4°C. Anti-β-actin 
and anti-ATP1A1 antibodies (1:5000) were used as reference controls for whole or membrane 
extracts, respectively. Membranes were incubated with IRDye secondary antibodies (1:10000) 
for 20 min at room temperature. Immunoreactive bands were detected by an Odyssey 
Infrared Imaging System (LI-COR Biosciences). 
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 Immunostaining 
HAoSMC were plated in 8-chamber μ-slides (IBIDI, Martinsried, Germany) and fixed for 10 min 
with 4% paraformaldehyde solution. Non-specific antibody binding was prevented using a 
blocking solution of 10% normal donkey serum (Jackson ImmunoResearch Laboratories) for 1 
h. Cells were incubated with the anti-MC1R, anti-MC4R and the anti-human/mouse/rat 
Caveolin-1 monoclonal (R&D research, Minneapolis, USA 1:100) overnight at 4°C, and then 
with DyLight-conjugated species-specific secondary antibodies (1:500) for 2 h at room 
temperature. In HAoEC proliferation experiments, cells were incubated with the anti-Ki67 
primary antibody, using the aforementioned conditions. Slides were finally incubated with 
DAPI (Sigma-Aldrich, 1:1000) for 5 min, mounted in a fluorescence mounting medium (Dako, 
Glostrup, Denmark), and examined with an ApoTome fluorescence microscope (Carl Zeiss, 
Jena, Germany). Data were analyzed using the ZEN software v.5.0 SP1.1 (Carl Zeiss). 
 Immunohistochemistry 
Formaldehyde-fixed paraffin 0.7 µm sections of a normal human aorta were obtained using a 
microtome (Leica RM 2145, Germany) and placed on glass slides. For immunostaining, slides 
were incubated with xylene and rehydrated by immersion in ethanol-series until rince with 
deionized water. After incubation with antigen retrieval (Dako, CA) at 96°C for 20 minutes, 
cooling and incubation with 3% hydrogen peroxide for 10 minutes, the PBS-washed slides 
were blocked with 5% BSA for 1 hour. Anti-rabbit MC1R and anti-rabbit MC4R (Alomone, 
Israel) 1:100 respectively diluted in PBS and 5% BSA, were applied O/N at 4 °C. Slides were 
incubated with a biotinylated goat anti-rabbit IgG secondary antibody (1:200; Vector 
Laboratories, Burlingame, CA) and signals were revealed using the VECTASTAIN Elite ABC-HRP 
kit combined with the ImmPACT DAB EqV peroxidase (HRP) substrate (Vector Laboratories). 
Sections were washed with PBS, counterstained with hematoxylin for 2 seconds end rinced 
with deionized water. As control of the staining specificity, the anti-MC1R and anti-MC4R 
antibodies were pre-incubated 30 min with their specific blocking peptides.  
 Intracellular cAMP 
Quantification of intracellular cAMP levels was performed using the cAMP ELISA kit (Enzo Life 
Sciences, USA). HAoECs and HAoSMCs were seeded to confluence in 96-well plates. Cells, prior 
to 5-min stimulation with α-MSH 10-8 M, were pre-treated for 30 min with IBMX 0.1 mM, to 
inhibit cAMP degradation by phosphodiesterases (PDEs). Forskolin was used ad positive 
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control. Cells treated with IBMX alone were used as controls. The concentration of α-MSH was 
selected based on previous publications on HDMECs (Hartmeyer, Scholzen et al. 1997; 
Scholzen, Brzoska et al. 1999) and pilot experiments that showed its effectiveness. 
 Directional cell migration assay 
HAoECs were treated with a solution of 2.5μM 1'-dioctadecyl-3, 3, 3', 3'-
tetramethylindotricarbocyanine iodide (DiR, Biotium, Hayward, CA) in complete medium for 
20 min at 37°C, washed and seeded onto 24-well plates with culture inserts (IBIDI). Inserts 
were removed to create a cell-free gap of approximately 500 µm, and HAoECs were allowed 
to migrate for 12h at 37°C and 5% CO2 in the presence of 10-8 M α-MSH or in medium alone. 
As a control for receptor-binding specificity, cells were pre-treated with the MC1R-selective 
competitive α-MSH antagonist 153N-6 (10-5 M) for 15 min. Plates were scanned with the 
Odyssey imaging system (LI-COR Biosciences) at 0, 3, 9, and 12 h, at 84μm resolution and high-
quality setting (emission, 800nm). Scans were converted to 8-bit images and analyzed with 
the NIH ImageJ software v1.38x. For time-course gene-expression analysis, 2 × 104 HAoECs 
were plated in high 35-mm dishes with culture inserts (IBIDI) and treated with α-MSH 10-8 M. 
  Intracellular Ca2+ mobilization assay 
Intracellular Ca2+ levels were measured using the Fluo-4 NW Calcium Assay Kit (Invitrogen). 
HAoECs, seeded onto a 24-well plate with IBIDI culture inserts in a calcium-free medium, were 
loaded with 400 μL of Fluo-4 NW for 30 min at 37°C and 5% CO2. Fluorescence was measured 
for 300 sec after treatment with α-MSH 10-8 M using an Infinite M200 PRO plate reader 
(excitation, 494 nm; emission, 516 nm). Thapsigargin (10-8 M) was used as positive control for 
Ca2+i release, treating HAoECs for 120 seconds before stimulation with α-MSH (10-8 M). Ca2+i 
changes were calculated as the difference between the area under the curve (AUC) before 
(resting levels) and after addition of stimuli. 
 Time-course gene-expression analysis on HAoECs 
To isolate RNA from cells undergoing directional migration assay, we used the Agencourt 
RNAdvance cell v2 kit (Beckman Coulter, Beverly, MA), following the manufacturer’s 
instructions. RNA extracted from migrating HAoECs at 0.5, 3, 6, and 12h was used for 
microarray analysis using the HumanHT-12 v4 Expression BeadChips (Illumina, San Diego, CA). 
Raw data were extracted by Illumina GenomeStudio, imported in R v2.15.2 and analyzed with 
the Lumi package. Data were normalized by variance stabilizing transformation (VST) and 
42 
 
robust spline normalization (RSN). Probes with a detection P-value < 0.01 in <10% samples 
were filtered out. 
To analyze the time-course microarray gene-expression experiments and the RNA sequencing 
data, we used the Short Time-series Expression Miner (STEM) v1.3.8 algorithm. Briefly, STEM 
implements a clustering method that lines up two steps. First, it selects a set of unique 
representative temporal profiles that, independently of the data, cover every possible 
expression profiles that can be generated in the experiment for a given set of parameters; 
second, it assigns to one of these temporal profiles only those gene profiles that pass the 
filtering criteria, as determined by a correlation coefficient. A permutation test was used to 
identify which profiles had a statistically significant enriched number of genes, and significant 
profiles were grouped into larger clusters by their correlation degree (≥ 0.7). The extent of the 
regulation is calculated as the maximum-to-minimum fold-change showed by the gene during 
the time-course. 
Microarray data were validated investigating mRNA expression of 84 wound healing related 
genes at different time points by real-time RT-PCR, using the Human Wound Healing RT² 
Profiler PCR Arrays (Qiagen Sciences, Frederick, MD) following the manufacturer’s 
recommendations. The concordance of microarray hybridization intensities (log2 
transformed) with PCR data (Ct) was measured by computing the Pearson correlation 
coefficient and assessing its statistical significance. Hierarchical clustering was performed 
using GENE-E v3.0.20 (https://software.broadinstitute.org/GENE-E). Analysis of functional 
relations among regulated genes was made using the DAVID Bioinformatics Resources v6.7 
(http://david.abcc.ncifcrf.gov/home.jsp), testing for multiple annotations, i.e. Gene Ontology 
(GO) terms, KEGG pathways, and the Swiss Prot (SP)-Protein Information Resource (PIR) 
keywords. Redundant GO terms were removed using the web-based tool REViGO. A network 
map of the enrichment analysis was produced by the Cytoscape program v2.8.2 using the 
Enrichment Map app, a network-based visualization method for gene-set enrichment results.  
 Radius migration assay 
Cell migration assays were performed using Radius™ 24‐Well Cell Migration Assay Kit (Cell 
Biolabs, Inc., San Diego, CA, USA) per manufacturers’ protocol. HAoSMC were grown on the 
pre‐treated Radius™ 24‐well cell migration plate (Cell Biolabs, Inc.) at 1.0 × 105/well for 24 hrs. 
Cells do not attach to the Radius™ gel spot area (~0.68 mm). The day after plates were treated 
with Radius™ gel removal solution to expose the cell‐free area to cell migration. After removal 
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of gel, cells were treated with the presence or absence of 10-10 M α-MSH to observe its effect 
on cell migration. Images were taken every 3 hours for 24 hours using a Zeiss ApoTome 
fluorescence microscope. 
 Transwell migration assay 
For Transwell migration assays, harvested cells (7x103cells) were plated onto the upper 
chamber of a Transwell® Permeable Supports (Corning, Lowell, USA) with 8μm pores (Costar). 
24 hours after we treated cells with specific compounds. At 48 hours cells were fixed with 4% 
paraformaldehyde in PBS, non-migrated cells on the upper side of the filter were removed 
with a cotton swab, and cells on the underside of the filter were stained with dapi. Images 
were captured using a Zeiss ApoTome fluorescence microscope. Relative cell migration was 
determined by the percentage of the migrated cells to the total number of the cells migrated 
in the control condition. For each experiment, the number of cells in nine random fields on 
the underside of the filter was counted, and two independent filters were analyzed. 
 Proliferation assay 
We measured cell proliferation using the Click-it® EdU Microplate Assay (Thermo Fisher 
Scientific, USA). We plated 1000 cells /well in a 96 well plate and after 24 hours we treated 
them. At 48 hours, corresponding to cell doubling time, the assay was performed accordingly 
to the manufacturer instruction.  
 RNA-sequencing of HAoSMC 
Two µg of total RNA were precipitated and poly(A)+ RNAs were enriched following 
MicroPoly(A) Purist kit protocol (Applied Biosystems). Libraries were prepared and pooled 
together using multiplex library RNA Barcoding reagents and Total RNA-Seq kits for the 
Sequencing by Oligonucleotide Ligation and Detection (SOLiD) System (Applied Biosystems). 
Complementary DNA (cDNA) amplification reaction was conducted with 20 µL template in 100 
µl end-volume reaction and with 16 PCR cycles. Clonal amplification of library templates was 
performed on SOLiD p1 DNA beads by emulsion PCR (ePCR) using 0.5 pM library template and 
E120 EZbeads scale. Three different sample libraries were seeded in each lane of a SOLiD flow 
chip (400 million p2-EZBeads) and templates were single-end sequenced [50 base pairs (bp) 
forward] on a SOLiD 5500xl System (Applied Biosystems). 
Using XSQTools (Applied Biosystems) with default parameters, we removed reads with low-
quality base values and generated .csfasta and .QV.qual files for each sample. Using TopHat 
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v2.0.11 with Bowtie 1 (D. Kim et al., 2013; Langmead, Trapnell, Pop, & Salzberg, 2009) to 
handle color space reads, we mapped all reads to the human genome version 
HG38/GRCh38.76 downloaded from the Ensembl database (Flicek et al., 2014). We excluded 
'haplotypes' and 'patches' sequences from the reference, in order to focus on primary 
assembly and to avoid under-estimation of gene expression. Then, we implemented the 
reference annotation based transcript (RABT) procedure, using Cufflinks suite v2.1.1 (Roberts, 
Pimentel, Trapnell, & Pachter, 2011; Trapnell et al., 2012), to create a new assembly for our 
downstream analysis, integrating information about known genes with those reads mapped 
in intergenic or intronic regions. Using the latter annotation, we identified novel transcripts 
and quantified them along with well-annotated genes. We estimated genes and transcripts 
expression levels by Cuffquant (using default parameters, apart from -multi-read-correct -
frag-bias-correct 'reference.fasta', and -max-bundle-frags 100.000.000) and then Cuffnorm 
(with default parameters, apart from -total-hits-norm). For each feature, we computed both 
reads counts and fragments per kilobase of transcript per million fragments mapped (FPKM) 
values. Genes with an FPKM value ≥ 0.05 in at least 80% of samples were considered 
expressed. This threshold was obtained by correlating RNA-Seq data with those from a qPCR 
gene expression array (TaqMan Array Human Inflammation, Applied Biosystems) in 
preliminary experiments (not shown). 
 Differential expression analysis on RNA-seq data 
Normalization procedures are a crucial step in the analysis of RNA-Seq data, since they may 
deeply affect the quality and quantity of differentially expressed genes. Here, we performed 
differential expression analysis controlling for "unwanted variation" (e.g. technical batch 
effects or other biological confounding variables) using the between-sample normalization 
method (R package RUVSeq) as proposed by Risso et al. (Risso, Ngai, Speed, & Dudoit, 2014). 
A set of empirical negative control genes, supposed not to be influenced by the biological 
covariates of interest (i.e. control and α-MSH-stimulated SMC), was used to estimate factors 
of unwanted variations (i.e. K parameter of the RUVs method). The number of k factors was 
chosen by comparing unadjusted with adjusted expression data by the use of diagnostic plots 
such as relative log expression (RLE) plots, scatter plot of first two principal components, and 
histogram plots of the distribution of the P values for testing differential expression between 
control and α-MSH-stimulated SMC. A k = 27 factors of unwanted variation was chosen in our 
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settings since it showed the best trade-off between data adjustment and the risk of data 
overcorrection. 
The negative binomial generalized linear model (GLM) approach implemented in the edgeR 
package was used to perform differential expression analysis between control vs. α-MSH-
stimulated SMC (Robinson, McCarthy, & Smyth, 2010). We deemed genes as significantly 
different at an FDR-adjusted P-value < 0.05. 
 Statistical analysis 
Data passed the Shapiro-Wilk test and/or the D'Agostino-Pearson omnibus test for normality. 
Homogeneity of variances among groups was assessed with the Brown-Forsythe test and 
Bartlett's test: between-group variances were similar and standard deviations not significantly 
different. The within-group variance was estimated by computing mean square error. 
Differences among groups were compared using either one-way ANOVA followed by Tukey’s 
multiple comparisons test, or two-way ANOVA (with treatment and time as factors) followed 
by Bonferroni post-hoc test, or two-tailed unpaired t-test, as appropriate. P-values < 0.05 were 
considered statistically significant. The analysis was done using GraphPad Prism v7 (GraphPad 
Software, La Jolla, CA). 
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Effects of MCRs activation on human aortic endothelial cells 
(HAoECs) 
1. HAoECs constitutively express a functional MC1R, but not POMC 
To determine which elements of the melanocortin system are expressed in human ECs from 
large vessels, we first performed a quantitative real-time PCR (qRT-PCR) for detecting specific 
mRNAs in six human primary cells, i.e. three aortic ECs (HAoECs) and three coronary artery 
ECs (HCAECs). All the macrovascular ECs clearly expressed MC1R, but no other known MCRs. 
Opposite to what was observed for human dermal microvascular EC (Scholzen, Brzoska et al. 
1999), we did not detect POMC in HAoECs. We detected the prohormone convertase PCSK1 
that process POMC into most of the derived peptides, but not PCSK2, which is needed to 
produce α-MSH (Seidah, Benjannet et al. 1999) (Table 1).  
 
 
 
 
 
 
 
 
Table 1| Expression of the MCRs, POMC, and prohormone convertases in primary human macrovascular 
endothelial cells HAoEC: human aortic endothelial cells; HCAEC: human coronary artery endothelial cells; HA: 
human astrocytes (positive control). Three different primary lines for each type of EC were analyzed by qRT-PCR: 
from c1,c4ECACC, c2,c5Lonza, and c3,c6Promocell. Detection levels are reported as: –, undetected; +, < 35 Ct; and ++, 
< 30 Ct.  
 
Given that MC1R is a highly polymorphic gene and that many variants are known to affect its 
signal transduction (Doyle, Fortin et al. 2012), we sequenced the MC1R open reading frame 
(ORF) of the six primary human artery ECs to identify and exclude from subsequent functional 
analysis those cells with gene variants that may interfere with the cellular response to MC1R 
ligands. All the three HCAECs bear a variant allele, whereas only two HAoECs did not present 
any polymorphism (Table 2). The variant alleles found have been associated with a decrease 
in cAMP production, in response to α-MSH stimulation (Xu, Thornwall et al. 1996; Schioth, 
Cell MC1R MC2R MC3R MC4R MC5R POMC PCSK1 PCSK2 
HAoEC 
c1, c2, c3 
++ – – – – – + – 
HCAEC 
c4, c5, c6 
++ – – –   – – + – 
HA ++ – – + – + ++ ++ 
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Phillips et al. 1999). We elected to use the HAoEC c2 cell line for functional tests due to its 
shorter doubling time. 
Table 2 | Mutational analysis of MC1R in primary human artery endothelial cells HAoEC: human aortic 
endothelial cells; HCAEC: human carotid endothelial cells. Primary cell lines from ECACC( c1, c4), Lonza (c2, c5), 
and Promocell (c3, c6). Melanocortin-1 Receptor (MC1R) Ref. Seq. NM_002386.3. 
 
To verify whether the three HAoECs express the MC1R protein, we performed an immunoblot 
analysis. We detected specific immunoreactive bands, corresponding to the molecular weight 
of the canonical fully active receptor (Sanchez-Laorden, Sanchez-Mas et al. 2006; Herraiz, 
Garcia-Borron et al. 2017), in total cell lysates and also in membrane extracts (Figure 1.1A), 
which showed that the MC1R receptor was expressed on the plasma membrane of the 
HAoECs. 
We then measured the changes in intracellular cAMP levels after treatment with α-MSH, to 
test whether confluent HAoECs express a functionally active MC1R. Indeed, in cells grown to 
confluence in the presence of the phosphodiesterase inhibitor IBMX, a 5-minute stimulation 
with α-MSH 10-8 M induced a significant increase of intracellular cAMP (Figure 1.1B). Co-
incubation with the MCR competitive α-MSH antagonist 153N-6 10-5 M (Chhajlani 1996) 
abolished the elevation of cAMP, indicating that MC1R is specifically activated by α-MSH 
(Figure 1.1B). 
Finally, to test whether HAoECs express MC1R in vivo, we performed immunohistochemistry 
staining for the receptor in formaldehyde-fixed paraffin sections of a normal human aorta. We 
Endothelial cell type SNP Genotype Position (nt) 
Amino acid 
substitution 
HAoECc1 - - - - 
HAoECc2 - - - - 
HAoECc3 rs885479 GA 1868 Arg163Gln 
HCAECc4 rs1805005 GT 1558 Val60Leu 
HCAECc5 rs1805005 GT 1558 Val60Leu 
HCAECc6 rs1805005 TT 1558 Val60Leu 
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observed a positive MC1R staining of endothelial cells, confirming the in vitro observations 
(Figure 1.1C). 
 
 
Figure 1.1 HAoECs express a functional MC1R (A) Immunoblot analysis of membrane extracts showed that all 
three studied primary cells express MC1R on the plasma membrane. A grey arrow (blot show below) indicates 
immunoreactive bands of 37 kDa specific for MC1R. The ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1) 
protein (light grey arrow) was analyzed as a membrane-specific loading control, to confirm proper identification 
of the plasma membrane fraction (above). Lanes are: M, molecular weight marker; c1, c2, and c3 are 3 different 
primary HAoECs (c1 – from ECACC, c2 – Lonza, and c3 – Promocell). (B) Intracellular cAMP concentrations were 
measured in confluent HAoECs after treatment with α-MSH 10-8 M for 5 min, with or without the MC1R-selective 
competitive α-MSH antagonist 153N-6. Results are shown as box plots, representing the average of N = 5 
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independent replicates. The box bounds the interquartile range (IQR) divided by the median and Tukey-style 
whiskers extend to a maximum of 1.5 × IQR beyond the box. *P < 0.05, based on one-way analysis of variance 
(ANOVA) followed by Bonferroni’s post-hoc test for preselected comparisons [F(3, 16) = 5.201, P = 0.0116]. (C) 
Immunohistochemical detection of MC1R in a normal human aorta specimen confirmed that HAoECs express the 
receptor in vivo (10×). To control for the specificity of the staining, we used the secondary antibody alone (left), 
the secondary antibody with the pre-adsorbed anti-MC1R antibody (center), and the secondary antibody with 
the anti-MC1R antibody (right): only the latter showed an intense, specific staining. 
 
2. α-MSH promotes migration of HAoECs via MC1R activation 
To determine whether MC1R activation has any influence on HAoECs migration and/or 
proliferation, we used a gap closure assay that measures directional cell migration. As shown 
in Figure 2.1A, stimulation with α-MSH 10-8 M enhanced HAoECs migration: in comparison 
with cells cultured in medium only, migration speed appeared to accelerate after 3 h of 
treatment and became significantly higher at 9 and 12 h in α-MSH-treated cells. Consistently, 
concomitant use of 153N-6 10-5 M was able to abolish the pro-migratory effect of α-MSH, 
whereas treatment with 153N-6 alone did not alter ECs migration speed (Figure 2.1A). Gap 
closure assays were also performed in the presence of the proliferation inhibitor PD0332991: 
as expected, blocking cell proliferation increased gap closure time, but the higher speed in α-
MSH-treated cells confirmed the enhancement in cell migration after MC1R activation, which 
was still significant at 9 and 12 h (Figure 2.1B).  
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Figure 2.1 MC1R activation enhances HAoEC migration (a) after insert removal, HAoEC monolayers were treated 
with α-MSH with or without the 153N-6 antagonist and allowed to migrate for 3, 9, and 12 h: migration into the 
wound was quantified using DiR cell staining and near-infrared fluorescence scanning. Results are shown as 
means ± s.e.m. (N = 6). **P < 0.01 and ***P < 0.001 α-MSH vs. medium alone (C), based on two-way ANOVA 
(interaction Time × Treatment) followed by Bonferroni post-hoc test [F (9, 80) = 2.957, P = 0.0044; F (3, 80) = 
10.85, P < 0.0001 for treatment effect]. (b) Using the same protocol as in panel B, we repeated the directional 
migration assay in the presence of the proliferation inhibitor PD0332991. Results are shown as means ± s.e.m. 
(N = 10). *P < 0.05 and **P < 0.01 α-MSH vs. medium alone (C), based on two-way ANOVA (interaction Time × 
Treatment) followed by Bonferroni post-hoc test [F (3, 72) = 3.018, P = 0.0353; F(1, 72) = 9.074, P = 0.0036 for 
treatment effect]. 
 
Conversely, no clear-cut effect of MC1R activation was observed on ECs proliferation, as 
documented by counting the number of Ki-67 positive cells, which were not significantly 
different between treated and untreated HAoECs (Figure 2.2). 
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Figure 2.2 MC1R activation does not significantly influence HAoEC proliferation. Quantification of Ki-67 positive 
cells in separate experiments showed no significant differences between control and stimulated HAoECs. Data 
are expressed as an average percentage of Ki-67 positive cells, counting 10 different fields for each treatment 
conditions using an ImageJ tool. Results are shown as a scatter dot plot with mean ± SD (n = 4 independent 
experiments). P = n.s. by one-way ANOVA. 
  
Since MC1R may signal through either cAMP increase or intracellular elevation of free 
cytosolic Ca2+ (Garcia-Borron, Sanchez-Laorden et al. 2005), we tested which signal 
transduction pathway was active in the enhancement of the HAoECs migration. Stimulation 
with α-MSH 10-8 M did not lead to an increase of intracellular cAMP in migrating HAoECs 
compared to control cells (Figure 2.3) On the contrary, MC1R activation resulted in a 
significant, rapid, and sustained increase in intracellular Ca2+ levels over the control, early after 
the removal of the insert in the cell migration assay (Figure 2.4A). This rise was almost 
completely abolished when HAoECs were pre-treated with the α-MSH antagonist 153N-6 10-5 
M, which in turn alone did not affect Ca2+ signaling. Comparisons of the areas under the curve 
(AUC) confirmed that the α-MSH-induced rise in Ca2+ levels was highly significant (Figure 2.4B). 
Incubation with thapsigargin 10-8 M, a non-competitive inhibitor of sarco/endoplasmic 
reticulum Ca2+-ATPases (SERCAs) that causes a rapid rise of cytosolic Ca2+ by depleting 
endoplasmic reticulum stores (Lytton, Westlin et al. 1991), did not prevent a further significant 
rise of Ca2+ in response to a subsequent stimulus with α-MSH (Figure 2.4C, 2.4D). This was 
only partially inhibited by pre-treating HAoECs with the α-MSH antagonist 153N-6 10-5 M. 
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Figure 2.4 MC1R activation increases intracellular calcium levels in migrating HAoECs. Treatment with α-MSH 
10-8 M after the removal of the insert in the cell migration assay induced a prompt increase in intracellular Ca2+ 
levels (a), which was completely abolished by pre-treatment with the MC1R-selective α-MSH antagonist 153N-
6. Intracellular Ca2+ was detected using the Fluo-4 NW fluorescent calcium indicator. The rise of intracellular 
Ca2+ in response to the stimulus with α-MSH was not prevented by previous stimulation with thapsigargin 
(THAPS) 10-8 M (b), which is known to increase cytosolic Ca2+ by depleting endoplasmic reticulum stores. This 
was partially inhibited by pre-treating HAoECs with 153N-6. (a, c) Arrows indicate the time when either 
thapsigargin or α-MSH were added. Curves represent the means ± s.e.m. of five separate experiments. RFU, 
relative fluorescence unit. (b, d) Measurement of the areas under the curve (AUC) was used to compare α-MSH-
induced effects with control treatments. AUC results are shown as box plots (N = 5 independent replicates per 
group), boxes are IQRs divided by medians, and whiskers are Tukey-style. *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001 in comparisons indicated by strait, horizontal lines, based on one-way ANOVA followed by 
Tukey’s multiple comparisons test (b) [F(3, 16) = 14.56, P < 0.0001] and (d) [F(3, 16) = 15.43, P < 0.0001]. 
 
3. MC1R activation dynamically regulated several gene modules.  
To evaluate the effects of MC1R activation at the transcriptional level, we assessed genome-
wide gene expression profiles at 0.5, 3, 6, and 12 h after stimulation with α-MSH 10-8 M vs. 
control in HAoECs cultured in the directional cell migration assay. Applying stringent filtering 
parameters, we deemed expressed 18936 of the 47231 measured transcripts (40%). 
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Comparative time-course analysis, using the STEM algorithm (Ernst and Bar-Joseph 2006), 
identified 637 genes whose expression consistently showed a median change ≥ 30% over time 
as an effect of stimulation with α-MSH. These genes fitted 57 of the 625 possible model 
profiles computed by the clustering algorithm. Five hundred and six transcripts were 
associated with 15 distinct temporal profiles that showed a statistically significant enriched 
number of genes at an FDR < 0.05 (Figure 3.1A). The remaining 131 genes were associated 
with model profiles that had an FDR > 0.05 and, thus, were deemed as potentially arising from 
noise by random chance and excluded from subsequent analysis. Interestingly, we did not 
observe any significant change in MC1R expression level in migrating ECs after stimulation 
with α-MSH at any time point. The 15 significant temporal profiles of differential expression 
were grouped, based on their similarity by a correlation coefficient ≥ 0.7, to form 6 different 
clusters (Figure 3.1B). Overall, genes belonging to clusters 1 and 4 showed a marked increase 
in expression at 6 h in treated vs. untreated cells, whereas genes in clusters 2 and 3 displayed 
a marked decrease at the same time point; conversely, genes in clusters 5 and 6 appeared to 
be upregulated at 3 h.  
 
Figure 3.1 Significant temporal expression profiles and clusters of genes modulated by MC1R activation. The 
STEM algorithm attributed a number to each model profile and profiles were ordered based on the P-value 
significance of number of genes assigned vs. expected. Six clusters groups different model profiles based on their 
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similarity by correlation coefficient ≥ 0.7. (a) List of significant expression profiles ordered by significance 
(nominal P-value) within each cluster profile. The number of genes belonging to a profile is also reported. (b) 
Heatmap depicting the temporal expression profiles of genes within each cluster. Genes were hierarchically 
clustered into 6 groups using one minus Pearson correlation distance and the average linkage method. Data are 
expressed as the average log2 gene expression ratio of α-MSH stimulated cells to non-stimulated cells (N = 3 
independent experiments per treatment group). Above the heatmap, the time scale (hours) of the time course 
experiments is reported. Globally normalized expression ratios are shown as a gradient color ranging from lower 
(blue) to higher (gold) values. 
 
Time-course expression data of control and α-MSH stimulated cells at 3 and 6 h were validated 
using PCR-based arrays profiling key genes involved in wound healing. Forty-eight genes were 
detected by both microarray and real-time PCR (Figure 3.2), with a strong positive correlation 
between their average signal intensities (r ≥ 0.8, P < 0.0001 for all pairwise correlations). 
 
 
Figure 3.2 Validation of microarray data of non-stimulated and α-MSH-stimulated migrating human aortic 
endothelial cells (HAoECs) by real-time RT-PCR arrays. We performed a confirmatory analysis of gene expression 
data on migrating HAoECs at 3 and 6h, using Human Wound Healing RT² Profiler PCR Arrays (Qiagen). On the y-
axis is the additive inverse mean Ct in control (C) and α-MSH-treated cells at a given time point; on the x-axis is 
the log2–transformed average raw signal intensity on microarray (N = 3 independent experiments per treatment 
group). We computed Pearson’s correlation coefficients (r) and reported within the plots along with significance 
P-values. Plots show data of 48 genes detected by both microarray and real-time PCR. 
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To uncover the biological meaning beneath these transcriptional effects, we performed a 
functional enrichment analysis of the 506 regulated genes. Forty-four terms were significantly 
enriched at P < 0.01 and FDR < 0.20 and were used to draw a network to visually interpret 
biological data (Figure 3.3). The most significant gene sets included the phosphoprotein class 
(P = 4.8 × 10-8, FDR = 1.9 × 10-5), the endomembrane system (P = 3.8 × 10-5, FDR = 1.3 × 10-2), 
and the ECM-receptor interaction (P = 2.3 × 10-4, FDR = 2.5 × 10-2). Notably, 197 of the 506 
regulated genes encode for phosphoproteins, 188 produce variant proteins by alternative 
splicing, and 65 are transcription factors or regulators. Importantly, 11 genes, i.e. AGRN, 
COL1A1, COL1A2, COL4A5, COL5A1, DAG1, ITGA2, ITGA10, LAMB1, LAMC1, and SPN, belonged 
to either the ECM-receptor interaction pathway or the extracellular matrix cellular 
component. To further analyze gene expression changes in a structured fashion, functionally 
enrichment analysis was performed associating annotated gene sets with the 6 different 
clusters of temporal profiles. Co-expressed gene subsets were visualized as temporal 
clustered profiles sharing functional annotations (Figure 3.3).  
Coupling time-course gene expression analysis to enrichment analysis allowed identifying 
significantly regulated genes that have never been associated with MC1R signaling before, 
including genes involved in ECM-receptor interaction, vesicle-mediated transport, SNARE 
protein complex formation, and metal ion binding through metal-thiolate cluster structures 
(metallothioneins, MTs). 
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Fig. 3.3 Modules of co-regulated genes in migrating HAoECs upon MC1R activation. Upper left: the enrichment 
map of regulated genes in α-MSH-treated migrating HAoECs was drawn as a network of the most significant 
functionally annotated gene sets (P < 0.01 and Benjamini FDR < 0.20). Nodes represent gene sets. Enrichment 
significance is encoded by node color intensity gradient from lower (light red) to higher (dark red). Node size is 
proportional to the gene set size. Gene sets are connected based on their similarity by green edges, and edge 
thickness measures the degree of the overlap between two gene sets (calculated using a cut-off of 0.375 of the 
Jaccard plus Overlap combined coefficient). Clusters of tightly and functionally related gene sets were manually 
circled and assigned an overall label. Right and lower left: heat maps of temporal expression patterns of relevant 
gene sets and pathways are displayed. Hierarchical clustering of genes was performed using one minus Pearson 
correlation distance and the average linkage method. Row normalized expression values are shown as a gradient 
color ranging from lower (blue) to higher (gold) values. 
58 
 
Effects of MCRs activation on human aortic smooth muscle 
cells (HAoSMCs) 
4. HAoSMCs constitutively express a functional MC1R, and MC4R but not 
POMC 
To investigate whether HAoSMCs expressed any melanocortin system component, we first 
analyzed the expression of MCRs and POMC by qRT-PCR for detecting specific mRNAs. We 
found that HAoSMCs expressed both MC1R and, at a lower level, MC4R. We did not detect 
other known MC receptors, nor the melanocortin precursor POMC (Table 3A). We confirmed 
this observation using the digital PCR (dPCR) technique, measuring the exact number of MCR 
mRNA copies expressed by HAoSMCs cultured in control growth media (Table 3B). As for ECs, 
we sequenced the MCR open reading frame (ORF) of the primary human artery SMCs to 
identify and exclude from subsequent functional analysis those cells with gene variants that 
may interfere with the cellular response to MCR ligands (data not shown).  
 
Cell MC1R MC2R MC3R MC4R MC5R POMC 
HAoSMC ++ – – + – – 
 
GENES Copies/µl 
 
MC1R 60.83 
MC4R 31.22 
 
Table 3 | Expression of the MCRs and POMC in primary human macrovascular smooth muscle cells 
HAoSMCs express MC1R and MC4R. (a) MCRs and POMC mRNA expression were tested by qPCR. HAoSMCs 
express MC1R and MC4R at a lower level but not POMC. Detection levels are reported as –, undetected; +, < 35 
threshold cycles (Ct); and ++, < 30 Ct (b) MC1R and MC4R mRNA expression was tested by PCR. The absolute 
quantitation for digital PCR results was reported as number of copies of mRNA per µ liters of samples loaded on 
a chip.  
 
To verify whether HAoSMCs express the MC1 and MC4 receptors on the membrane, we 
performed a western blot and an immunofluorescence analysis. We detected by western blot 
A 
B 
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on total and membrane extracts the immunoreactive bands corresponding to the molecular 
weight of different isoforms of the MC1 and MC4 receptors. In detail, we could identify bands 
of 37kDa corresponding to the glycosylated monomeric form of MC1R in the total whole 
extract and a putative functional dimeric 58kDa band (Sanchez-Laorden, Sanchez-Mas et al. 
2006) in both total and membrane specific extracts. We identified only the dimeric 58kDa form 
of MC4R, and not the monomeric form, in both total and membrane extracts. The 42kDa band 
of β-actin (positive cytoplasmic control) was visible only in the whole extract, thus assuring 
that the observed immunoreactive bands in the extracts are specific for the plasma membrane 
(Figure 4.1A). 
We further showed by immunocytochemistry (ICC) that the MCRs co-localized with caveolin, 
a specific membrane protein (Rothberg, Heuser et al. 1992) (Figure 4.1B). MC1R and MC4R 
were clearly detectable on cell membranes and the membrane co-localization was measured 
using the Pearson’s colocalization coefficients for all the images taken with the confocal 
microscope (Figure 4.1C).  
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Fig 4.1 HAoSMCs express MC1R and MC4R on the membrane. (A) WB on whole and membrane protein extracts. 
Anti ATP1A1 antibody was used as membrane marker, beta-actin as a cytoplasmic marker. Bands of 37kDa and 
58kDa were detected in the whole extract while only the dimeric form is expressed in the membrane. (B) MC1R 
and MC4R protein expression were tested by ICC using specific anti-MCR antibodies (green) and Caveolin (red) 
was used as membrane marker. (C) The graph showed the Pearson’s co-localization coefficients for MC1R and 
MC4R with Caveolin measured on single confocal images from three independent experiments.  
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Finally, to test whether HAoSMCs express MC1R and MC4R in vivo, we performed 
immunohistochemistry staining for the receptors in formaldehyde-fixed paraffin sections of a 
normal human aorta. We observed a positive staining of SMCs and ECs for MC1R, and a 
positive staining of SMCs for MC4R, confirming the in vitro observations (Figure 4.2). 
 
 
Figure 4.2 Immunohistochemical detection of MC1R and MC4R in a normal human aorta specimen confirmed 
that HAoSMCs express the receptor in vivo (10×). To control for the specificity of the staining, we used the 
secondary antibody alone (left); in the middle is shown in brown the positive staining for MC1R in the 
endothelium and in the tunica media; the slice on the right shows the MC4R expression in the tunica media. 
 
MCRs are G-protein coupled receptors (GPCRs) associated with cAMP production, and so we 
measured the changes in intracellular cAMP levels after treatment with α-MSH, to test 
whether confluent HAoSMCs express functionally active MCRs. We observed that 5-minute 
treatment with α-MSH increased cAMP production and that α-MSH dose was inversely 
correlated with cAMP production. Indeed, concentrations of 10-10 and 10-12 M caused a 
significant rise in intracellular cAMP, in the presence of the phosphodiesterase inhibitor IBMX, 
compared to the control, non-treated cells (Figure 4.3). We chose the α-MSH concentration 
of 10-10 M to perform all subsequent experiments.  
MC1R MC4R 
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Figure 4.3. HAoSMCs express functional MCRs. The graph shows the increase in cAMP production after 
treatment with decreasing concentrations of α-MSH. We used scalar doses of α-MSH from 10-8 to 10-12 M. The 
latter concentration corresponds to the physiological concentration in human plasma. Forskolin (Fsk) was used 
as a positive control. The ELISA assay showed dose-dependent effects of α-MSH on MC1R activation (n=7). 
*p<0.05, ***p<0.001 vs. Ctrl; 1-way ANOVA followed by Bonferroni test.  
 
5. The activation of MCRs modulates HAoSMC phenotypic changes 
Morphology is the main parameter that defines the SMC phenotype. Contractile SMCs are 
elongated, spindle-shaped, whereas synthetic SMCs are less elongated and have a 
cobblestone morphology, defined as epithelioid or rhomboid (Owens, Kumar et al. 2004; 
Rensen, Doevendans et al. 2007). To determine whether α-MSH affects SMC morphology, we 
treated cells with a single-pulse of α-MSH 10-10 M for 48h: cell images were taken every 3h 
by an Apotome Zeiss microscope. We analyzed cells shape using an Image J v1.47 plug-in that 
automatically measures minor and major cellular axis. Treatment with α-MSH significantly 
promoted HAoSMCs elongation with peak effects at 6-12 h after treatment (fold difference of 
the number of elongated cells with respect to control = 2.6, p<0.01) (Figure 5.1).  
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Figure 5.1 α-MSH promotes HAoSMC spindle-shape contractile morphology. Comparison of the ratio of pole-
to-pole length (long axis/short axis) between cells. The graph represents a time course analysis of the number of 
cells with a higher than five ratio of length. *p<0.05, **p<0.01. 
 
To confirm the phenotypic modulation of HAoSMCs, we analyzed by qRT-PCR the expression 
level of smooth muscle α-actin (ACTA2), smooth muscle myosin heavy chain (SM-MHC), 
calponin (CNN1) and SM22-alpha (TGLN), which are the most representative markers of the 
contractile phenotype (Rensen, Doevendans et al. 2007; Beamish, He et al. 2010). These genes 
were more expressed in HAoSMCs treated with α-MSH 10-10 M compared with untreated cells 
(Figure 5.2A). Immunocytochemistry imaging of HAoSMCs stained with anti-smooth muscle 
α-actin (α-SMA) and SM22-α were consistent with the observed changes in cell morphology 
after treatment with α-MSH and confirmed the increased protein expression of the typical 
markers of the contractile phenotype (Figure 5.2B).  
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Fig. 5.2 α-MSH is able to modulate HAoSMCs phenotypic switching from a synthetic to a contractile form. (a) 
Gene expression analysis of markers of the contractile phenotype; the graph shows the DDCt values over the 
control of ACTA2, SM-MHC, CNN1, and TGLN. Mean ± SD, n=5. *p<0.05, **p<0.001 vs. control. (b) 
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Immunofluorescence staining for α-SMA(red) and SM22α, (green), confirming the phenotypic changes. 
Fluorescence quantification indicated that treatment with α-MSH significantly increased α-SMA and SM22-α 
expression. Fluorescence intensities were normalized on nuclei number counting. Mean ± SD n=4, **p<0.001, 
***p<0.0001 vs. control. 
 
6. Activation of MC1R modulates HAoSMC migration with mild effects on 
proliferation. 
SMC phenotypes commonly show differences in the rate of proliferation and migration 
(Rensen, Doevendans et al. 2007): elongated, contractile cells migrate and proliferate less 
than the synthetic ones. To determine the effects of α-MSH on HAoSMC migration, we 
performed two different types of assay: a gap-closure assay for directional migration and a 
modified Boyden chamber assay through a gradient of PDGF-BB for chemotaxis. We 
performed a time course experiment by analyzing gap closure every 3 h for 12 h. α-MSH 
treatment slows down HAoSMC migration with the maximum effect between 6 and 9 h (mean 
fold difference = 4.9, p<0.001). Pre-treatment with the proliferation inhibitor PD0332991 did 
not abolish α-MSH-mediated acceleration in gap-closure, confirming that MCR activation had 
specific effects on migratory pathways (Figure 6.1).  
Figure 6.1. MCR activation slows down HAoSMC migration. (a) Wound healing time lapse migration assay show 
a slow in cells migration in treated cells compared to the control in presence of the proliferation inhibitor 
T0 
t0 t3 t6 t9 t12 t26
0
50
100
ctrl PD
MSH
-10
M PD
*
%
 w
o
u
n
d
 a
re
a
66 
 
PD0332991. *p< 0.05 vs Ctrl; 1-way ANOVA followed by Bonferroni test. (b) Representative images of gap 
closure. At 9h after α-MSH treatment, there is a significant difference over the control in the percentage of 
closure.  
  
Likewise, in the transwell migration assay treatment with α-MSH reduced the number of 
migrating cells (mean fold difference = 1.95, p<0.01). Treating the cells with the MC1R specific 
inhibitor MSG606 (Cai, Stankova et al. 2013) reverted the effect. Instead, the treatment with 
JKC-363, the most selective and potent MC4R inhibitor (Kim, Small et al. 2002; Verty, 
McFarlane et al. 2004), was not able to contrast α-MSH-dependent reduction in migration, 
suggesting that the effect was due to MC1R activation (Figure 6.2). 
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Figure 6.2. MC1R activation slows down HAoSMC migration. (a) The graph shows the percentage of migrated 
cells in treated and untreated conditions reduced the number of migrating cells (mean fold difference 1.95, 
p<0.01) and treating the cells with the MC1R specific inhibitor MSG606 reverted the effect, opposite JKC-363, 
the MC4R inhibitor didn’t contrast α-MSH effect.***p< 0.001 vs Ctrl; 1-way ANOVA followed by Bonferroni test. 
 
We finally analyzed the role of MCRs activation on HAoSMC proliferation by a modified BrdU-
incorporation assay. We treated cells with increasing doses of α-MSH for 24 hours and we 
showed that nanomolar concentrations of the melanocortin peptide were able to slightly but 
significantly reduce HAoSMCs proliferation (mean fold difference = 1.2, p<0.05) (Figure 6.3).  
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Figure 6.3 MCR activation reduce HAoSMC proliferation. BrdU proliferation assay indicated that α-MSH had a 
mild, but significant effect on cell proliferation (mean fold change 1.2, p<0.05). Mean ± SD, *p<0.05 vs. control. 
 
7. α-MSH reduces HAoSMC cell migration modulating the p38MAPK/HSF 
pathway  
To identify which pathways were activated after α-MSH administration, we performed a time-
course RNA sequencing analysis of the transcriptome of HAoSMCs. We detected as expressed 
12172 genes and we performed an analysis on the differentially expressed genes at 3, 6, 9 and 
12 hours after α-MSH treatments. We obtained a list of genes significantly up and down 
regulated after α-MSH treatment grouped in time course profiles (data not shown). We chose 
to focus on the genes differentially expressed at 6 hours since this was the time preceding the 
maximum difference in cell phenotype and migration. We then performed a Gene Set 
Enrichment Analysis to identify the clusters of modulated genes that correlated with biological 
and functional pathways. Using Cytoscape and the Enrichment Map software, we generated 
a representative network of the positive or negative regulated clusters that are associated 
with biological processes (Figure 7.1). The map showed that α-MSH treatment negatively 
regulated pathways involved in the regulation of SMC migration and proliferation, in wound 
healing, and in extracellular matrix organization (blue nodes, bold-highlighted labels). These 
data support the results of the phenotypic assays and suggest that α-MSH reduces SMC 
migration and proliferation promoting the contractile phenotype. 
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Figure 7.1 The enrichment map of regulated genes in α-MSH-treated HAoSMCs was drawn as a network of the 
most significant functionally annotated gene sets (P < 0.01 and Benjamini FDR < 0.20). Nodes represent gene 
sets. Enrichment significance is encoded by node color intensity gradient from lower (light red, blue) to higher 
(dark red, blue). Node size is proportional to the gene set size. Gene sets are connected based on their similarity 
by green edges, and edge thickness measures the degree of the overlap between two gene sets (calculated using 
a cut-off of 0.375 of the Jaccard plus Overlap combined coefficient). 
 
Finally, we performed a Gene Set Enrichment Analysis to identify significant gene sets that 
were putatively associated with specific transcriptional factors. We found three gene clusters 
under the control of specific transcriptional factors significantly modulated by the α-MSH 
treatment (Table 4). In particular, we found genes under the control of Heat shock factor-1 
(HSF1), which is known to regulate cell migration (Salinthone, Tyagi et al. 2008); SRY-Box 9 
(SOX9), which regulate vascular smooth muscle cell differentiation (Xu, Ji et al. 2012); and NK2 
Homeobox-5 (NKX2.5), which is involved in the regulation of Collagen Type I (Ponticos, 
Partridge et al. 2004).  
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Table 4 | Transcriptional factors that control set of genes negatively modulated after α-MSH treatment. The 
table reports the three gene sets under the control of the cited transcriptional factors that are modulated after 
α-MSH treatment. In columns are reported the gene set size, the enrichment score (ES), the normalized ES and 
the adjusted p-value. 
 
HSF1 is a substrate for p38 Mitogen-Activated protein kinases (p38MAPK) (Dayalan Naidu, 
Sutherland et al. 2016) and it is known that p38MAPK activation drive cell migration in vascular 
SMC (Kavurma and Khachigian 2003). Therefore, we treated cells for 5, 10, 15 minutes with α-
MSH and we showed by WB that p38 phosphorylation was decreased by MC1R activation in a 
time-dependent manner (Figure 7.2 A-B).  
These data suggest that a negative modulation of the p38MAPK/HSF1 pathway is a key 
mechanism of action underlying MC1R control on SMC migration (see Figure 7.3 below).  
 
Figure 7.2 MC1R activation modulates HAoSMC migration through the p38MAPK/HSF pathway. (a) WB relative 
quantification of the bands of p38MAPK and phospho-p38MAPK. Each bar represents the mean of three different 
experiments per condition (Mean ± SD, *p<0.05, **p<0.001 vs. control, n=5). (b) Representative WB image of 
p38MAPK reduction in phosphorylation after treatment with α-MSH for 5/10/15 minutes.  
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Figure 7.3. Cartoon of MCR mechanism in controlling SMC migration 
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DISCUSSION 
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Maladaptive vascular remodeling is one of the primary cause of artery dysfunction and/or 
occlusion. We provided evidence for a new function of peripherally expressed melanocortin 
receptors, i.e. regulation of EC and SMC motility, which may contribute to vessel homeostasis 
and the control of cellular processes that lead to maladaptive remodeling. Our study opens 
new possibilities to treat/prevent those cardiovascular diseases where remodeling plays a 
major role. 
This work showed that human macrovascular ECs and SMCs constitutively express functional 
MCRs. In particular, human aortic ECs express MC1R, and human aortic SMCs express MC1R 
and MC4R. We showed that activation of MC1R drives faster ECs migration in an in vitro 
wound healing model, by enhancing intracellular Ca2+. Time-course gene expression analysis 
allowed us identifying downstream molecular pathways associated with the enhanced ECs 
motility following α-MSH engagement of the MC1R. On the other hand, we showed that 
treatment with α-MSH promoted the switch from synthetic to contractile phenotype, slowed 
down migration, and reduced proliferation of human aortic SMCs. Consistently, we showed a 
time-dependent gene expression modulation of pathways associated with SMC migration and 
proliferation. We found that p38MAPK phosphorylation and HSF1 expression decreased after 
α-MSH treatment, and we propose a model in which MC1R activation controls aortic SMC 
migration through the p38MAPK/HSF1 pathway. 
To our knowledge, this is the first demonstration that human macrovascular ECs and SMCs 
express MCRs and modify their phenotype and behaviors in response to their natural ligand, 
α-MSH. These observations revealed that the MCRs expressed peripherally in the human 
macrovasculature could be a target to treat and/or prevent maladaptive remodeling and 
related conditions.  
 
Constitutive expression and cell-type restricted function of 
MC1R in HAoECs 
We detected both the MC1R mRNA and protein in HAoECs and demonstrated that it was 
functionally active, since resting confluent cells were able to produce cAMP in response to 
exogenous α-MSH. No other component of the MC system was detectable in HAoECs. 
Consistently, we did not detect α-MSH in cell culture supernatants. Thus, HAoECs are not a 
source of MC peptides but may be targeted by endocrine secretion (by the pituitary gland) or 
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paracrine release of endogenous agonists (e.g. by immune cells at injured sites) (de Angelis, 
Sahm et al. 1995; Rensen, Doevendans et al. 2007). These findings represent a peculiar 
difference between macrovascular and microvascular ECs, as it has been reported that 
HDMECs express POMC and release MC peptides upon stimulation (Scholzen, Brzoska et al. 
1999). In addition, unlike the microvascular ECs (Hartmeyer, Scholzen et al. 1997), MC1R 
expression did not significantly change upon exposure of the HAoECs to α-MSH. This finding 
suggests that in macrovascular ECs MC1R expression levels are not influenced by pathways 
that depend on its activation and that HAoEC migration is not dependent on MC1R 
upregulation. Considering EC heterogeneity, these results underline that artery ECs present 
cell type-restricted gene expression, which may account for a specific physiological function 
for MC1R, other than anti-inflammatory actions. This hypothesis led us to investigate whether 
MC1R activation could affect macrovascular EC migration after injury.  
 
MC1R activation on HAoECs drives migration through the Ca2+ 
signaling cascade 
EC migration is a fundamental process primed by damage and involved in vascular 
homeostasis and repair (Al-Soudi, Kaaij et al. 2017). Our data revealed that MC1R activation 
by α-MSH increased the rate of HAoEC migration, both in gap-closure and in injury-induced 
wound-healing assays, without significantly affecting cell proliferation. This effect was 
specifically induced by MC1R activation, since the 153N-6 peptide antagonist at MC1R 
abolished the α-MSH-driven migration of HAoECs, reverting it to the same rate of control cells. 
Conversely to our observations, it has been recently reported that α-MSH inhibits in vitro 
migration of HUVECs (Weng, Huang et al. 2014); but this reinforces our idea that EC are 
heterogeneous and the pro-migratory effect of α-MSH via MC1R activation is restricted to 
arterial ECs of the macrovasculature. EC migration is an essential step in wound closure after 
injury (Li, Huang et al. 2005; Michaelis 2014), and increased migration could promote the 
faster repair of the lesions.  
Interestingly, MCRs can signal through an intracellular cAMP increase or transient intracellular 
elevation of cytosolic free Ca2+ (Bhasin, Yuan et al. 2010). In migrating HAoECs, α-MSH elicited 
a prompt elevation of intracellular Ca2+ but not of cAMP, suggesting that MC1R activation 
drives EC migration through the Ca2+ signaling cascade. This is coherent with the known effect 
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of Ca2+ mobilization on EC migration (Cines, Pollak et al. 1998). Ca2+ gradients regulate cell-
ECM interactions responsible for the asymmetry between the cell front and rear adhesions, 
finally resulting in cellular directional movement (Li, Huang et al. 2005). Consistent with this, 
we observed a dynamic co-regulation of molecular pathways and cellular processes that 
appear to drive the faster closure of the wound (Cines, Pollak et al. 1998; Otsuka, Finn et al. 
2012). Our finding suggests that MC1R activation promotes HAoEC migration mostly by 
regulating interactions between cell membrane integrin receptors and dystroglycan with their 
ECM counterparts, i.e. collagens, laminins, and agrin. Integrins and interstitial collagen 
influence directional migration, and this may be a key effect of the MCS in repairing large 
vessels. 
 
MC1R activation in migrating HAoECs dynamically regulates 
expression of genes that control cellular trafficking and 
molecule mobilization. 
Time-series genome-wide gene-expression analysis on migrating HAoECs showed that α-MSH 
treatment significantly affected large gene-sets; this indicates that MC1R activation has a wide 
influence on pathways playing a prominent role in regulating cellular activity. MC1R activation 
also modulated genes associated with the endomembrane system and intracellular organelle 
lumen, suggesting a role in controlling cellular trafficking and molecule mobilization. 
Remarkably, MC1R engagement with α-MSH modulated the ECM-receptor interaction 
pathway, which is known to be critical for the directional EC migration (Davis and Senger 
2005). Conversely, MC1R activation did not affect the expression of cell cycle-related genes, 
which was consistent with the apparent lack of regulation of HAoEC proliferation in the gap 
closure assay. Our findings suggest that the regulation of the ECM components, i.e. collagens 
and laminins, and of their receptors, i.e. integrins and dystroglycans, through MC1R may drive 
higher HAoEC motility. Binding of integrins to type-I collagen suppresses cAMP production and 
the activity of cAMP-dependent protein kinase A: consequently, actin polymerization is 
induced, contributing to the formation of stress fibers and to EC contractility, which finally 
generates the directional movement (Whelan and Senger 2003). This is consistent with the 
idea that the fine-tuning of integrins and their binding molecules promoted by MC1R 
activation plays a key role in conditioning HAoEC migration rate. In addition, MC1R stimulation 
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induced an early upregulation of SNARE proteins (which mediate vesicle-membrane fusion) 
and cytoplasmic vesicle genes, followed by a later overexpression of metal-binding proteins. 
Importantly, trafficking and delivery/fusion of vesicle proteins are essential for the regulation 
of front-rear polarity during directional cell migration (Skalski, Yi et al. 2010; Lizama and Zovein 
2013). 
 
Smooth muscle cells express functional melanocortin receptors 
We have shown that HAoSMCs express mRNA and proteins of MC1R and MC4R but did not 
express POMC. It has already been demonstrated that MC1R is expressed on human cerebral 
(de Angelis, Sahm et al. 1995) and cutaneous (Hartmeyer, Scholzen et al. 1997) microvascular 
EC and on human umbilical vein ECs (Rinne, Nordlund et al. 2013), but the expression in 
arterial macrovasculature cells has not been investigated yet. The receptors were functionally 
active since treatment with α-MSH increased cAMP production in HAoSMC. 
Peripheral expression of MC1R is known to be involved in the control of inflammation 
(Catania, Gatti et al. 2004) and regulate melanocyte, melanoma cell (Zhu, Lalla et al. 2004), 
lymphocytes (Brod and Hood 2008), and neutrophils (Capsoni, Ongari et al. 2007) migration; 
expression on macrovascular SMCs suggested local effects on these cell types. 
The MC4R expression on HAoSMC, instead, opens new horizons about peripherally receptor 
functions. MC4R has never been reported in human peripheral tissues: this receptor has been 
located in the central nervous system and studied for its implication in energy homeostasis 
and metabolic processes (Tao 2010). Ligand-induced activation of brain MC4R results in 
inhibition of food intake and stimulation of energy expenditure, promoting a negative energy 
balance (Balthasar, Dalgaard et al. 2005). In mice, treatment with a specific MC4R agonist 
controls plasma level of LDL cholesterol by reducing liver PCSK9 expression (Clemmensen, 
Finan et al. 2015). Therefore, we may speculate that peripherally expressed MC4Rs could be 
sensors for the metabolic status of the cells. 
 
MCR activation promotes the contractile phenotype and 
decreases proliferation and migration of the HAoSMCs 
Concerning human aortic SMCs, differently from ECs, we observed that α-MSH treatment 
decreased cell migration. Moreover, it promoted the switch from a synthetic to a contractile 
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phenotype and reduced cell proliferation. The effects of α-MSH observed on vascular SMC 
migration is consistent with the multiple evidence that this peptide is able to modulate 
migration of different cell types, such as melanoma cells (Zhu, Lalla et al. 2004), lymphocytes 
(Brod and Hood 2008), and neutrophils (Capsoni, Ongari et al. 2007). 
Vascular SMC phenotypic switching, migration and proliferation are hallmarks of vascular 
remodeling, which in turn underlies onset and progression of pathological processes such as 
neointima hyperplasia, vessel stenosis, and atherosclerosis (Owens, Kumar et al. 2004). 
Promotion of SMC contractile phenotype by MCR activation is in line with melanocortin anti-
inflammatory properties: vascular SMCs, in fact, respond to pro-inflammatory molecules by 
switching from a contractile, quiescent to a synthetic, proliferative and pro-migratory 
phenotype (Owens, Kumar et al. 2004; Beamish, He et al. 2010). We showed that in human 
aortic SMCs the protein markers of the contractile phenotype (α-SMA, SM-MHC) were up-
regulated after α-MSH treatment and we showed a concomitant change in cell morphology in 
vitro: the cells were more elongated than the control cells with a higher ratio of axis length. 
The phenotypic control of SMCs is a fundamental step to avoid neointima formation in 
pathological vascular remodeling. In vitro studies showed that treatment of rat aortic SMCs 
with Rosiglitazone, a PPAR (peroxisome proliferator-activated receptor) agonist, inhibited 
the switch from contractile to synthetic phenotype. In vivo treatment with Rosiglitazone 
significantly inhibited the neointima formation in rat carotid artery after angioplasty (Yang, 
Kim et al. 2013). Rapamycin, used in drug-eluting stents,  inhibited in vivo intima hyperplasia 
in both human and animal model; in vitro, Rapamycin promotes vascular SMC contractile 
phenotype (Martin, Merenick et al. 2007). Opposite to the above-mentioned compound, α-
MSH is an endogenous peptide with potent anti-inflammatory proprieties (Catania, Lonati et 
al. 2010) able to maintain the vascular homeostatic state: given the absence of side effects in 
preclinical studies on inflammatory diseases, it could be proposed as a better therapy to 
control remodeling and neointima formation. In parallel with the phenotype switch, α-MSH 
reduced HAoSMC migration, and proliferation. We showed that HAoSMC migration decreased 
in response to α-MSH even in presence of a chemoattractant molecule such as PDGF-BB. 
Previous studies showed the involvement of the melanocortin system in the regulation of cell 
migration and proliferation, in particular of inflammatory cells: α-MSH reduced secretion of 
IL-8 e Gro-α, pro-inflammatory cytokines and halted monocyte migration through 
inflammatory sites (Genedani, Bernardi et al. 1990). Moreover, α-MSH reduced T-lymphocytes 
77 
 
(Cooper, Robinson et al. 2005), neutrophils (Capsoni, Ongari et al. 2007) and eosinophils 
(Catania, Gatti et al. 2004) migration. α-MSH regulates migration and proliferation of 
keratinocytes in inflammatory conditions (Schauer, Trautinger et al. 1994) and exerts anti-
proliferative and anti-migratory actions on melanoma cells (Zhu, Lalla et al. 2004). In other 
cases, opposite to our findings, α-MSH seems to have pro-proliferative properties and 
mitogenic effects, in particular on melanocytes (Suzuki, Cone et al. 1996), but this effect 
is linked with one of its primary homeostatic functions, i.e. melanogenesis and protection 
from UV. 
 
The activation of MCRs locally expressed on HAoSMC 
downregulate cluster of genes implicated in cell migration and 
proliferation 
Molecular profiling of human cells/tissues represents an effective approach to unveiling the 
“fingerprint” of any changes occurring in response to environmental challenges, different 
healthy/disease state, or specific genetic/epigenetic programs. Therefore, to corroborate the 
effects we observed on SMC migration and proliferation, we investigated the transcriptome 
of α-MSH-stimulated SMCs to associate modulated gene expression patterns with specific 
biological functions. We focused our analysis on samples collected at hour 6 of the time-
course migration assay, since, at this time point, we expected to find the main gene expression 
changes explaining the larger migration differences observed at 9 hours between α-MSH-
stimulated vs. non-stimulated SMC. 
Gene set enrichment analysis revealed that the treatment of SMC with α-MSH was strongly 
associated with a lower expression of genes implicated in cellular migration and proliferation, 
wound healing and ECM deposition. Consistently, these findings fit with the results obtained 
in a gap-closure migration in vitro assay on α-MSH-stimulated SMC, thus supporting a role for 
MC1R activation in the down-regulation of vascular SMC migration and proliferation. 
To identify specific transcriptional programs that might help to reconstruct the mechanism of 
action that would lead to a decreased SMC migration/proliferation through MC1R activation, 
we performed a gene set enrichment analysis using transcription factor targets gene sets. This 
approach would have allowed us to identify transcription factors that could likely associate 
with significant gene sets in either α-MSH-stimulated SMC or control cells. We found that the 
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transcription factors HSF1, SOX9, and NKX2.5 were significantly associated with down-
regulated genes in α-MSH-stimulated SMC. Notably, these transcription factors are known to 
control the expression of genes implicated in cellular migration (Salinthone, Tyagi et al. 2008), 
vascular SMC differentiation (Xu, Ji et al. 2012), and regulation of Collagen Type I (Ponticos, 
Partridge et al. 2004), respectively, suggesting that the phenotypic changes we observed on 
SMC after α-MSH stimulation are orchestrated by precise signaling pathways. In this context, 
we hypothesized that the possible mechanism that specifically links MC1R activation and SMC 
migration would act through the down-regulation of and/or interference in the HSF1 signaling. 
 
HAoSMC migration is modulated by the downregulation of the 
P38MAPK/HSF1 pathway 
HSF1 controls the expression of heat shock proteins (HSPs) and previous work established 
that increased expression of HSPs in the vessel wall might evoke proinflammatory and 
autoimmune reactions in the pathogenesis of atherosclerosis (Berberian, Myers et al. 
1990; Zhu, Quyyumi et al. 2001). Moreover, HSF1 was highly expressed as well as 
activated in atherosclerotic lesions of hypercholesterolemic rabbit model (Metzler, Abia 
et al. 2003) and mouse HSF1 deficiency alters cardiac redox homeostasis and increases 
mitochondrial oxidative damage (Yan, Christians et al. 2002). HSF1 is a substrate for 
p38MAPK (Dayalan Naidu, Sutherland et al. 2016) and it is known that p38MAPK 
activation drives cell migration in vascular SMC (Hedges, Dechert et al. 1999; Kavurma 
and Khachigian 2003). p38MAPK is activated by mitogenic and migratory stimuli, such as 
by pro-inflammatory cytokines of immune-cells under stress condition (Coulthard, White 
et al. 2009; Rose, Force et al. 2010). Some studies demonstrated that p38MAPK pathway 
inhibition in pathologic condition prevented neointima formation. In vitro inhibition of 
p38MAPK phosphorylation blocked vascular SMC polarization in response to mechanical 
stress (Chen, Qin et al. 2003). In a rabbit in vivo model of artery injury, chemical inhibition 
of p38MAPK slowed down vascular remodeling (Ju, Nerurkar et al. 2002). Moreover, in 
mice, p38MAPK pathway inhibition halted vascular SMC proliferation, DNA replication 
and Rb protein phosphorylation (Proctor, Jin et al. 2008). It is also known that p38MAPK 
is a key element in the regulation of pro-inflammatory molecule transcription and 
translation. Substrates downstream the pathway of p38MAPK, such as TNF-α, IL-1 and the 
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HSP, are among the main factors involved in atherosclerotic progression (Spagnoli, 
Bonanno et al. 2007). 
We showed here, for the first time, that the p38MAPK pathway is de-activated in 
response to the stimulation of MC1R in macrovascular SMC. Moreover, we showed that 
HSF1 expression is downregulated and we propose that the negative modulation of the 
p38MAPK/HSF1 pathway is the mechanism of action underlying MC1R control on SMC 
migration. As mentioned above, p38MAPK is a key player in vascular remodeling and 
different studies in the last 20 years focus on the inhibition of this pathway searching for 
a system to avoid systemic effects (Coulthard, White et al. 2009; Church, Martin et al. 
2015). Melanocortin receptor expressed on macrovascular cells could be an effective 
target to modulate the p38MAPK pathway locally and consequently control maladaptive 
vascular remodeling.  
 
Limitations 
The main limitation of our study is that we do not have an in vivo model to confirm the role of 
MCR activation in remodeling and neointima formation directly on injured arteries. We might 
perform future experiments on conditional knockout mice for MC1R and MC4R in SMC and 
EC. 
Relevance and conclusions 
Consistent with the known peripheral effects of MC1R activation (Zhu, Lalla et al. 2004; 
Capsoni, Ongari et al. 2007; Brod and Hood 2008), we showed for the first time that its 
activation with α-MSH controls human aortic EC and SMC migration. Intriguingly, the effects 
on migration are different in the two cell types. Our data revealed that MC1R activation by α-
MSH increased the rate of HAoEC migration in a wound-healing gap-closure assay, without 
significantly affecting cell proliferation. Opposite, α-MSH decreased the rate of HAoSMC 
migration, both in a gap-closure and in transwell-chemotactic assays. This effect was 
specifically induced by MC1R activation, since the MC1R antagonist, but not the MC4R 
antagonist, was able to revert the migration rate to the same of the control cells. These data 
suggest strictly cell-related peripheral effects of α-MSH on the macrovascular cells, which 
upon injury or pro-inflammatory stimuli could regulate cells behavior locally promoting 
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endothelial repair and avoiding neointima formation, thus contrasting the hallmark events in 
vascular remodeling (Mulvany, Baumbach et al. 1996; Owens, Kumar et al. 2004).  
Considering our results, it could be interesting to test exogenous ligands of melanocortin 
receptors as potential drugs to modulate vessel function/dysfunction in a pathological state. 
The small size of α-MSH makes it an attractive molecule for drug design. Melanocortin 
analogs, such as Melanotan I and II have already been used in human as tanning agents to 
increase eumelanin production to protect against UV-induced DNA damage (Hadley ME, Dorr 
RT., 2006). Importantly, recent studies propose the use of α-MSH analogs to treat skin cancer 
and melanoma formation (Raposinho PD et al., 2008; Quinn et al., 2010).  There is also a great 
interest in MC4R as target for the design of novel therapeutics to treat disorders of body 
weight, such as obesity and cachexia (Fani L. et al., 2014). We may suppose a positive effects 
of the administration of α-MSH analogs to control the inflammatory state in vessel pathologies 
such as atherosclerosis or re-stenosis processes. Giving that the MCS contributes to the 
restoration of homeostasis in an perturbed system, melanocortin administration could 
modulate the main aspects of pathological vascular remodeling, promoting endothelial repair 
and SMC switching to the contractile form. Finally, since systemic administration of α-MSH 
analogs may control a wide spectrum of body functions, we envisaged applications as locally 
delivered drugs.  
For instance, a possible clinical application of our studies should be the development of new 
drug-eluting stents with local deliver of melanocortin peptides to antagonize re-stenotic 
processes without affecting EC proliferation and wound closure. Drug-eluting stents (DES) 
have excellent outcomes over the short to medium term, but stent thrombosis and in-stent 
restenosis are possible adverse consequences of stent implantation. Second-generation 
stents are coated with more specific, more effective and selective anti-proliferative agents, 
which have lower systemic toxicity and do not delay endothelial healing such as Everolimus 
and Zotarolimus. Last studies focused on strategies that aim at re-endothelialization of the 
stent struts combined with effective approaches to prevent smooth muscle cell proliferation 
and migration (Puranik, Dawson et al. 2013; Byrne, Joner et al. 2015): in this contest, MCR 
activation by melanocortins could be an interesting target. Since the melanocortin system is 
an endogenous system with potent anti-inflammatory proprieties (Catania, Lonati et al. 2010) 
and able to maintain the vascular homeostatic state, targeting MC1R could be an alternative 
and promising strategy to treat in loco the endothelial lesion or dysfunction and to prevent 
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SMC phenotypic switch, proliferation, and migration caused by pathologic remodeling or stent 
implantation. 
In conclusion, our results provide new knowledge about MCS involvement in vessel 
homeostasis and, possibly, on melanocortin modulation of vascular inflammation and 
remodeling. The use of anti-inflammatory molecules such as α-MSH could represent a strategy 
to prevent and heal endothelial dysfunction in macrovascular arteries and to maintain SMCs 
in the differentiated state or to revert their phenotype from a proliferative state. MC1R could 
represent a target for new therapeutic strategies aimed at preventing/repairing endothelial 
injury and neointima formation in a variety of cardiovascular pathological conditions. 
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